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ABSTRACT 
 Systemic sclerosis is an autoimmune connective tissue disorder associated with 
fibrosis of the skin and internal organs. Co-inhibitory receptors (Co-IRs) regulate 
immune responses and have been shown to control autoimmune phenotypes. We 
explored the role of these receptors in systemic sclerosis through their expression in 
circulating lymphocytes and their control of lymphocyte function in vitro and in vivo. We 
found that individual co-IRs were increased on specific lymphocyte populations in 
patients. PD-1 was increased on CD4+ memory T cells, while TIGIT was increased on 
both CD4+ and CD8+ memory T cells. Changes in TIM-3 expression were limited to 
cytotoxic NK cell populations while LAG-3 remained low and unchanged on all 
lymphocyte populations identified. The blockade of PD-1 in vitro, in particular, had a 
greater effect on modulating cytokine production in systemic sclerosis PBMCs compared 
to the blockade of TIGIT and TIM-3 versus a similar modulation of cytokine production 
by PD-1, TIGIT, and TIM-3 in healthy controls. This indicates an increased level of 
exhaustion in PBMCs from systemic sclerosis patients that can be overcome by the 
blockade of PD-1, but not TIGIT or TIM-3. However, the blockade of TIM-3 in vitro had 
  vii 
the greatest effect on modulating the production of soluble factors that regulate pro-
fibrotic changes in gene expression in systemic sclerosis fibroblasts. In vivo, TIGIT and 
TIM-3 were unable to consistently regulate the autoimmune phenotype of 
sclerodermatous GvHD mice. These data indicate a potential function for lymphocyte 
exhaustion in regulating the autoimmune and inflammatory response in systemic 
sclerosis, with specific co-IRs playing defined roles in disease pathogenesis.  
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PREFACE 
“There is of course a great deal we don’t know, and much of which we think we 
know we haven’t known, or thought we’ve known, for long.” 
- Bill Bryson “A Short History of Nearly Everything” 
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CHAPTER ONE: INTRODUCTION 
Systemic Sclerosis 
 
Clinical Significance and Treatments 
 Systemic Sclerosis is an autoimmune connective tissue disorder associated with 
vascular damage, fibrosis and immune dysregulation (Van Den Hoogen et al., 2013). 
While it is a rare autoimmune disorder, effecting roughly 30 in 100,000 Americans (Gu et 
al., 2008), it is the deadliest of the rheumatological or is it “rheumatic” ? diseases with a 
reported 10-year survival rate of roughly 50 (Elhai et al., 2012) to 70 (Steen and 
Medsger, 2007) percent. Patients typically present with Raynaud’s due to vascular 
damage in their extremities and progresses to a skin thickening in their fingers, hands and 
arms. Involvement of internal organ fibrosis and vascular damage causes the greatest 
morbidity and mortality, with patients succumbing to a number of complications 
including scleroderma renal crisis, interstitial lung disease (ILD), and pulmonary arterial 
hypertension (PAH).  
 Clinicians classify patients based on the development of skin disease. Patients 
with limited SSc (lSSc) develop skin disease in their distal extremities and face alone 
while diffuse SSc (dSSc) patients also have skin involvement on proximal extremities 
and trunk (Van Den Hoogen et al., 2013). This classification is linked to clinical 
outcomes with lSSc patients being more likely to develop vascular damage in their lungs 
leading to PAH and dSSc patients possessing a greater risk for pulmonary fibrosis 
manifesting as ILD and scleroderma renal crisis (Pattanaik et al., 2015).
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 Few treatments are available for these patients, with much of the focus being on 
treatment of symptoms, not the disease itself. The advent of ACE inhibitors for the 
treatment of scleroderma renal crisis has reduced mortality due to renal disease, but lung 
complications have proved harder to manage (Steen and Medsger, 2007). Fibrosis in the 
lungs leads to ILD and a loss of thin walled alveoli and the development of scar tissue 
(Joshua et al., 2014). Although the majority of patients survive more than 5 years after ILD 
diagnosis (Joshua et al., 2014), many patients eventually succumb to their loss of lung 
function, and ILD is responsible for over 30% of SSc deaths (Steen and Medsger, 2007). 
Few treatments are available and the standard of care is the immune-suppressive drug 
mycophenylate mofetil (Walker and Pope, 2012), immunoablation, and stem cell transplant 
(Sullivan et al., 2018). Vascular damage in PAH includes the obliteration of smaller vessels 
in the lungs, putting strain on larger blood vessels and right ventricle, leading to heart 
failure. PAH is also responsible for about 30%of SSc deaths (Joshua et al., 2014). While 
there are now several treatments for PAH targeting the vasculature, including endothelin 
receptor antagonists, PDE5 inhibitors, and NO and NO pathway, soluble guanylate cyclase 
activator, and prostacyclin analogs (Walker and Pope, 2012), treatment targeting the 
underlying cause of disease is lacking. 
 The most potent treatment of SSc has come with the development of autologous 
stem cell transplant where patients have CD34+ stem cells isolated and stored before being 
treated with myeloablative therapy, chemotherapy with or without radiotherapy, followed 
by a reconstitution of their immune system with their own stored stem cells (Sullivan et al., 
2018). Up to a third of patients respond to therapy, but it comes at a high cost, since 
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roughly 5-10 percent of patients die within 2 years of treatment, often due to opportunistic 
infections from a compromised immune system as a result of immune-ablation (Tyndall, 
2011). While this treatment is often effective and speaks to the important role the immune 
system plays in disease pathogenesis, it also shows the need for safer and more effective 
treatments.
 
Genetic and Environmental Factors 
 GWAS studies of SSc patients have shown HLA alleles have the greatest 
association with the development of SSc (Martin et al., 2014), with a variety of other loci 
being linked as well, and including those associated with immune function such as IL-2 
and IRF5 (Pattanaik et al., 2015). Despite some genetic links, less than 5% of 
monozygotic twins match for SSc development, making genetic predispositions only a 
small piece of the puzzle (Feghali-Bostwick, Medsger and Wright, 2003). 
 With a low penetrance of SSc among both twins in twin studies, the potential role 
of environmental factors becomes evident. Unfortunately, few studies have drawn 
positive links directly to environmental factors and SSc development. Silica exposure has 
been linked to SSc development, but cannot explain most diagnoses (Allanore et al., 
2015). Other environmental factors like fetal microchimerism (Pattanaik et al., 2015) and 
viral infections (Allanore et al., 2015) have also been explored. However, to date no clear 
link has been made from direct environmental exposure of some sort to the development 
of SSc (Pattanaik et al., 2015). 
 
 4 
 
 
Pathology and Immune System Involvement 
  Systemic sclerosis is defined as an autoimmune connective tissue disorder and 
much of the vascular and fibrotic abnormalities are thought to be influenced by immune 
dysregulation (Pattanaik et al., 2015). 
 SSc patients are typically lymphopenic, reflecting a decrease in total circulating 
lymphocytes (Gupta, S. Malaviya, N. Rajagopalan, P. Good, 1979). Specifically, 
decreases in CD8+ T cells and Natural Killer (NK) cell percentages have been reported 
(Almeida et al., 2015). The percentages of circulating anti-inflammatory T regulatory 
cells (Tregs) has been reported as decreased (Papp et al., 2011), increased (Rodŕguez-
Reyna et al., 2012), and unchanged (Klein et al., 2009). Differences in the definition of 
Tregs might explain some of the discrepancies, for example the use of the transcription 
factor FoxP3 to classify Tregs versus the cytokine receptors CD25 and CD127. Also the 
use of immune-suppressants, or the potential of the heterogeneity of the disease, such that 
different studies focus on different cohorts of patients, could also help explain these 
inconsistencies. Functionally, Tregs are reported as dysfunctional and are less 
suppressive in SSc patients than in healthy controls (Fenoglio et al., 2011). 
 Patients also have documented B cell abnormalities with the production of auto-
antibodies (Van Den Hoogen et al., 2013). The production of anti-nuclear antibodies 
(ANAs) are common in rheumatic diseases (Solomon et al., 2002). SSc patients typically 
show positive ANAs and typically produce one of several different specific 
autoantibodies: the most common being anti-topisomerase I, anti-RNA polymerase III, 
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and anti-centromere (Gu et al., 2008). Anti-topo I and anti-RNA pol III are often 
enriched in dSSc while anti-centromere is most often seen in lSSc (Allanore et al., 2015). 
Anti-nuclear protein responses have also been documented in the T cell compartment 
with topoisomerase-specific T cells being characterized (Fava et al., 2016). 
 Other immune cells in circulation have also been described as dysfunctional. 
Circulating monocytes in SSc patients have increased levels of the type I lectin siglec-1, 
possibly indicating an increase in a type 1 interferon response (York et al., 2007). Upon 
in vitro LPS stimulation, SSc monocytes produce more of the chemokine CCL18, a 
known inducer of collagen production in fibroblasts (Mathai et al., 2010). NK cells are 
also affected in SSc and they have been reported as having decreased cytokine production 
and cytotoxicity in SSc patients (Horikawa et al., 2005).  
 Recently groups have begun to explore tissue-specific immune dysregulation. 
Tregs in the skin of SSc are reported to be decreased in number and shown to produce 
less TGFβ and IL-10 (Antiga et al., 2010). Increased numbers of CD8+ T cells produce 
the pro-fibrotic cytokine IL-13 in the skin of SSc patients indicating a link between 
fibrosis and T cell function (Fuschiotti et al., 2013). Monocytes are thought to be a major 
player in SSc skin fibrosis. Gene expression of SSc skin has highlighted an increase in 
CD14, a monocyte marker (Lisa M. Rice et al., 2015) as well as other monocyte genes, 
including CCL2, MS4A4A, and CD163, which are predictive of progressive disease (Lisa 
M Rice et al., 2015). It has also been hypothesized by some groups that monocytes could 
migrate to tissue sites and transition to become pro-fibrotic αSMA-positive fibroblasts 
(Binai et al., 2012).  
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There is evidence that the type of T cell response in SSc could be altered. Within CD4+ T 
cells there has been reported to be a decrease in the number of TH1 type IFNγ-secreting 
cells with an increase in IL-17-producing cells TH17 cells (Fenoglio et al., 2011). 
Additionally, there is an increase in IL-17 in the serum and the skin of SSc patients 
compared to HCs (Needleman, Wigley and Stair, 1992), although not all studies have 
seen significant differences (Scala et al., 2004). TH2 cytokines like IL-4 and IL-13 have 
been shown to directly skew macrophages towards an M2 like phenotype and promote 
the production of TGFβ (Eloranta et al., 2010; Huang et al., 2015). TH2 T cells have been 
shown to express the IL-33 receptor ST2 (Schmitz et al., 2005) which is increased in SSc 
patients and positively correlates with skin score (Rice et al., 2017). IL-33 itself, which 
acts as a chemoattractant for TH2 cells (Komai-Koma et al., 2007), is also increased in 
SSc patients (Yanaba et al., 2011). The increase in TH2 cytokines and TH2 mediators in 
SSc as well as the direct role of the TH2 cytokine IL-13 on fibrosis demonstrates how 
studying and understanding this skewing of the immune response in SSc is of paramount 
importance.  
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Figure 1. Dysregulated Immune Responses in SSc 
Cytokines IL-4 and IL-13, associated with TH2 cells (blue), are increased in the blood 
along with IL-33 which targets TH2 cells via the IL-33 receptor ST2. Soluble ST2 levels 
are also increased in the blood of SSc patients. Monocytes (solid green) in circulation 
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express elevated levels of siglec-1 indicating a type 1 interferon response. Tissues, 
especially the lungs and the skin, have increased CD8+ T cells (purple) that secrete pro-
fibrotic factors like IL-13 which directly stimulate fibroblasts to produce collagen as well 
as stimulate tissue resident CD163+ macrophages (green nucleus) to secrete TGFβ to 
increase collagen production by fibroblasts (tan). 
 
sclGvHD as an Animal Model of SSc 
Patients that develop chronic-graft-versus host desease (cGvHD) after a bone 
marrow transplant often progress to sclerodermatous GvHD (sclGvHD), which is a 
fibrotic type disease that closely mimics SSc (Aractingi, Selim; Chosidow, 1998). This 
phenotype makes it an attractive inducible in vivo system for use in studying SSc. Early 
studies showed that the transfer of bone marrow from a wild type B10.D2 mouse into an 
irradiated wild type Balb/c mouse produced a chronic graft versus host reaction with 
features of human sclGvHD (Jaffee and Claman, 1983). SclGvHD in this system 
produces fibrosis in the skin and internal organs, similar to human SSc, and 
immunological abnormalities, like the production of ANAs, are reproduced in this model 
(Ruzek et al., 2004). Although often not included in reviews of this model (Beyer et al., 
2010), there is also some evidence of vascular damage with the development of 
hypermuscularized vessels (Ruzek et al., 2004). The observation of fibrosis, immune 
dysfunction, and vascular damage mimic the three hallmarks of SSc and make murine 
sclGvHD a useful animal model to study human SSc. 
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 The main driver of sclGvHD are CD4+ T cells and these  T cells alone are 
sufficient to produce a sclGvHD phenotype (Hamilton, 1987). Due to the importance of 
CD4+ T cells, splenocytes, a rich source of T cells, can be used to initiate disease instead 
of bone marrow (Ruzek et al., 2004). Successful engraftment has also been shown in 
recipient Balb/c Rag2-/- mice- that do not produce mature functional B or T cells, 
allowing for a non-irradiated mouse to recapitulate the sclGvHD phenotype (Ruzek et al., 
2004). The use of splenocytes from donor B10.D2 mice and the availability of Rag2-/- 
Balb/c mice provide an easily inducible system for the generation of the sclGvHD mouse 
model of SSc.  
 
Co-Inhibitory Receptors 
 
Introduction 
 Co-inhibitory receptors (co-IRs) are brake mechanisms for the immune system 
that consist of a group of receptors overlapping in some basic functions (Anderson, Joller 
and Kuchroo, 2016). These receptors play an important role in modulating immune 
responses, especially in autoimmune diseases. In vivo settings showcase the truly 
remarkable power of these receptors. One of the first receptors to be identified and 
characterized was CTLA-4. Mice lacking CTLA-4 die within the first few weeks of life 
from a lymphoproliferative disorder (Tivol et al., 1995). CTLA-4 is not the only co-IR to 
cause a spontaneous autoimmune phenotype; mice lacking the gene for the receptor PD-1 
also develop lupus-like symptoms (Nishimura et al., 1999). Other co-IRs have the ability 
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to temper autoimmune phenotypes with type 1 diabetes prone non-obese diabetic (NOD) 
mice having accelerated disease when they lack the co-IR PD-1 (Ansari et al., 2003) 
and/or LAG-3 (Okazaki et al., 2011). TIM-3 knockout mice develop worse experimental 
autoimmune encephalitis (EAE), a mouse model of multiple sclerosis (MS) (Monney et 
al., 2002). These in vivo systems display the important role co-IRs have in controlling 
autoimmunity. While these receptors are integral to modulating immune responses they 
are often found to be markers of immune dysfunction and exhaustion. Co-IRs are 
upregulated upon immune activation (Fuertes Marraco et al., 2015) and chronic antigen 
stimulation can lead to further upregulation of these receptors and an overall decrease in 
immune function (Singer et al., 2016). Blocking these receptors can restore effector 
function and reverse immune exhaustion (Barber et al., 2006; Jin et al., 2010). 
 In humans, chronic immune stimulation produces similar phenotypes linked to co-
IR expression. HIV infection can lead to increases in PD-1, TIM-3, and others (Day et 
al., 2006; Jones et al., 2008; Chew et al., 2016) and correlates with a decrease in effector 
T cell function.  
 The role of co-IRs in decreasing effector function of immune cells is manipulated 
in the case of many cancers. Often cancer microenvironments will have increases in the 
expression of ligands for co-IRs, for example PDL-1, the ligand for PD-1, which upon 
binding to PD-1 decreases the efficacy of T cells to kill the cancer cells (Zhang, Gajewski 
and Kline, 2009). New drugs have taken advantage of this phenomenon with blocking 
antibodies to PD-1 and CTLA-4 showing clinical success in remobilizing immune 
responses to cancer (Topalian et al. 2014; F. Hodi, 2010).  
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Lymphocyte Exhaustion 
 Lymphocyte exhaustion is loosely defined as a state of dysfunctional effector 
functions linked to an altered transcriptional profile. This state is maintained by high 
levels of co-IRs on the cell surface of exhausted lymphocytes (Wherry, 2011). Clinically, 
this state has been mostly reported and studied in the case of chronic viral infections and 
cancer. The use of blocking co-IRs remains an effective way to modulate this phenotype 
in vivo, cementing their role in lymphocyte dysfunction (Wherry, 2011). Although much 
of the description of exhaustion in humans has been limited to chronic viral infections 
(Day et al., 2006; Bengsch et al., 2010) and cancer (Chauvin et al., 2015), animal models 
and some basic human work has shown lymphocyte exhaustion to also be an important 
player in autoimmunity (McKinney et al., 2015). 
 Exhaustion was first described in detail by Dr. Ahmed’s group as a Sisyphean-
like effort by virus specific CD8+ T cells to control chronic LCMV infection. Sisyphus, a 
tragic figure from antiquity, as punishment for his sins, must forever labor to push a 
boulder up a hill without ever being allowed to complete his task. The group chose 
analogy because it seemed so similar to activated CD8+ T cells’ chronic inability to 
control the infection they were primed to fight (Zajac et al., 1998). Exhausted T cells 
proliferate less and produce less cytokines and are less cytotoxic which makes them less 
effective in vivo (Wherry, 2011).  
 T cell dysfunction leading to exhaustion is a progressive process best described in 
chronic infections. As an infection persists and viral load increases there is a shift 
towards fewer and fewer effective immune responses. Cytokine production is 
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incrementally decreased and less and less proliferation occurs in virus-specific cells. An 
increase in apoptosis is seen in exhausted cells as cells become more primed for cell 
death, compounded by the decrease in the production of cytokines essential for survival, 
such as IL-2. As this progression towards greater and greater exhaustion occurs co-IR 
expression increases as more types, as well as higher levels, of co-IRs are seen on the 
surface of exhausted cells (Wherry, 2011). 
 PD-1 was the first co-IR to be linked to exhaustion. PD-1 is increased on 
exhausted CD8+ T cells in mice chronically infected with LCMV. Blockade of PD-1 
restores effector function in these exhausted cells, indicating that not only is PD-1 a 
marker of exhaustion, but it also plays a role in maintaining decreased effector functions 
(Zajac et al., 1998; Barber et al., 2006). This observation held true in human chronic viral 
infections as well. Patients with HIV, hepatitis C virus (HCV), and hepatitis B virus 
(HBV) also have a similar phenotype of T cell exhaustion linked to PD-1 expression 
(Wherry, 2011).  
 The co-IR TIM-3 is also increased in the LCMV model. Interestingly it was often 
found co-expressed with PD-1 and indicated even greater levels of exhaustion. Not only 
did it indicate less effector function in vitro, the co-blockade of PD-1 and TIM-3 led to 
greater restoration of effector function and viral clearance in vivo (Jin et al., 2010). These 
observations suggested a potential additive effect of co-IRs where increasing levels of 
exhaustion are indicated by the expression of more co-IRs and the reversal of exhaustion 
is dependent on targeting a combination of different receptors. Co-expression of PD-1 
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with other receptors including TIGIT and LAG-3 (Matsuzaki et al., 2010) have supported 
the additive role of co-IRs in decreasing effector function further.  
 This combinatorial aspect of co-IRs has been exhaustively explored in the cancer 
field. Cancer is a perfect storm for exhaustion with chronic neo-antigen stimulation 
layered with often high levels of co-IR ligands to drive decreases in effector function 
(Baumeister et al., 2016). The blockade of PD-1 alone has been explored clinically and 
FDA approved PD-1 blockade is currently in the clinic, targeting melanoma and lung 
cancer, and is being expanded to be used in a variety of other cancer types (Li et al., 
2016). Despite the clinical success in some patients, the response rate of patients to 
blocking PD-1 hovers below 50% for most cancers (Zou, Wolchok and Chen, 2016), and 
the concept of combinatorial therapy is being explored (Baumeister et al., 2016). The 
combination of blocking PD-1 as well the co-IR CTLA-4 has been met with some 
success with response rates increasing with the blocking of both receptors 
simultaneously, although toxicity also increased (Wolchok et al., 2013).  
 Pre-clinically a variety of other co-IRs are being explored to take advantage of the 
role of multiple receptors leading to ever deeper levels of exhaustion. The co-blockade of 
PD-1 and LAG-3 in murine tumor models led to a greater level of tumor clearance (Woo 
et al., 2012). TIM-3 has also been explored in a similar manner with the co-blockade of 
PD-1 and TIM-3 being more effective at promoting tumor clearance (Sakuishi et al., 
2010). This data has supported the push for clinical trials testing the co-blockade of 
LAG-3 and PD-1 in malignancies (NCT02658981). 
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 Exhaustion is often driven by a complex transcriptional profile controlled 
increasingly by epigenetic changes that can eventually lead to an irreversible exhaustion 
phenotype. A comparison of the transcriptional profiles of exhausted versus memory cells 
shows a decrease in cell cycle and DNA replication genes juxtaposed by an increase in 
genes associated with the regulation of activation in the exhausted cell subset (Doering et 
al., 2012). While this finding is unsurprising, it supports the conclusion that exhausted 
cells proliferate less and are less functional. Follow up studies have found that these 
changes are regulated by epigenetic changes and exhaustion can be reversed by blocking 
these epigenetic changes from occurring (Ghoneim et al., 2017).  
 Most of the characterization of exhaustion has been explored in T cells, but the 
role of co-IRs in exhaustion in NK cells has not been overlooked. In murine tumor 
models, NK cells rapidly migrate to tumor sites, but become exhausted within tumors and 
are unable to kill tumor cells they previously could kill in vitro (Gill et al., 2012). A way 
to increase the cytotoxicity of NK cells is by blocking TIM-3, the co-IR the most highly 
expressed on NK cells (Ndhlovu et al., 2012). This has physiological relevance with 
TIM-3-mediated control of NK cytotoxicity being observed at the maternal-fetal-
interface during pregnancy (Sun et al., 2016).  
 The link between co-IR expression and lymphocyte exhaustion provides evidence 
for the importance of co-IRs in the control of immune responses. Many co-IRs that 
regulate specific aspects of the immune response and mediate exhaustion have been 
identified (Zhang and Vignali, 2016), and new ones are still being discovered. Our study 
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focused on the roles of PD-1, TIGIT, TIM-3 and LAG-3 and we, therefore, describe 
current knowledge about these four co-IRs in more detail below. 
 
PD-1 
 Programmed cell death protein 1 (PD-1) is one of the best characterized and most 
clinically utilized of the co-inhibitory receptors. A potent inhibitor of T cell function the 
blockade of PD-1 signaling can be used to increase T cell function in vivo (Yang, 2015). 
Its clinical relevance and potent role in T cell dysfunction makes it an attractive potential 
player in immune-mediated dysfunction in an autoimmune setting.  
 The molecule PD-1 was first discovered on a T cell hybridoma stimulated with 
phorbol 12 myristate 13-acetate (PMA) and ionomycin. This strong stimulus can drive 
lymphocyte proliferation and effector function, but also promotes a high rate of apoptotic 
cell death (Ishida et al., 1992). Due to the high rate of apoptosis in such strongly 
stimulated cells, the authors named the protein after the programmed apoptotic cell death 
they observed (Ishida et al., 1992). A few years later it was discovered that although PD-
1 was unregulated on activated lymphocytes it was not required for apoptosis, making the 
name “programmed cell death protein 1” a misnomer (Agata et al., 1996). 
 PD-1 is a transmembrane glycoprotein similar in structure and sequence with the 
costimulatory molecule CD28 and the co-inhibitory receptor CTLA-4, although different 
enough to not bind to B-7 molecules (Freeman et al., 2000). In fitting with its inhibitory 
functions, both immune-receptor tyrosine-based inhibitory motif (ITIM) and an immune-
receptor tyrosine-based switch motif (ITSM) are found on its cytoplasmic tail (Yokosuka 
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et al., 2012). Upon ligation of PD-1 by its ligands PDL-1 (Freeman et al., 2000) or PDL-
2 (Latchman et al., 2001) SHP-2 is recruited to the ITSM which leads to SHP-2 
dephosphorylating Syk in B cells (Okazaki et al., 2001) and CD3ζ and ZAP70 in T cells 
(Yokosuka et al., 2012) decreasing BCR and TCR signaling respectively. The decrease in 
signaling mediated by PD-1 leads to a decrease in cell proliferation and cytokine 
production which is heavily dependent on BCR signaling in B cells and TCR signaling in 
in T cells (Okazaki et al., 2001; Yokosuka et al., 2012). 
  This decrease in proliferation and effector function by PD-1 has significant in 
vivo consequences. Mice lacking PD-1 spontaneously develop a lupus-like disease and 
the CD8+ T cells in these mice were observed to have increased proliferative potential 
(Nishimura et al., 1999). This role in controlling lymphocyte function was further 
supported by the fact that autoimmune mouse models were made worse without PD-1 
function. NOD mice that spontaneously develop type 1 diabetes had accelerated disease 
if the mice lacked the gene for PD-1 (Ansari et al., 2003). EAE is increased in severity 
upon the blockade of PD-1 (Ansari et al., 2003).  Other animal models of autoimmunity 
including collagen II induced arthritis, a model of rheumatoid arthritis (RA), and a model 
of myocarditis also have been shown to be modulated by PD-1 (Zamani et al., 2016).  
 As previously discussed, an exhaustion phenotype and a role for reversing 
exhaustion by blocking PD-1 signaling has been well-characterized in the emerging field 
of immuno-oncology. Early trials of blocking PD-1 in cancer had success in late stage 
melanoma and follow up studies have led to its approval for lung and kidney cancer 
(Baumeister et al., 2016). Melanoma typically has a high burden of somatic mutations 
 17 
 
and the response rate to blocking PD-1 correlated with the mutation rate of the tumor, 
supporting the idea that neo-antigens drive an adaptive immune response that can be 
reinvigorated by blocking the co-IR, PD-1 (Rizvi et al., 2015). Response rates were also 
higher in patients that expressed PDL-1 in their tumors, showing that blocking this 
ligand-receptor interaction can promote an immune response against cancer (Taube et al., 
2014). After treatment with PD-1, certain TCR clones were enriched compared to 
baseline in patients that responded the therapy, presumably supporting the idea that 
blocking PD-1 promotes a reverse of an exhaustion phenotype that otherwise could 
suppress proliferation of tumor specific clones (Tumeh et al., 2014).  
 Further supporting the role of PD-1 in autoimmunity, patients treated with anti-
PD-1 therapy in cancer often have manifestations of autoimmune disease (June, 
Warshauer and Bluestone, 2017). While this provides a further hurdle in the treatment 
and care of cancer patients, it provides a human in vivo system showing PD-1’s potential 
role in autoimmunity.  
 PD-1 is a potent inhibitor of lymphocyte function and its role with autoimmune 
phenotypes and exhaustion make it an attractive target for study in a disease driven by 
immune dysfunction.  
 
TIGIT 
 T cell Ig and ITIM domain (TIGIT) is another co-inhibitory receptor emerging as 
an important player in regulating immune responses. Identified by multiple groups 
simultaneously and given different names Vstm3 (Levin et al., 2011), TIGIT (Yu et al., 
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2009), and WUCAM (Boles et al., 2009) , TIGIT was quickly linked to immune function. 
This co-IR was found to be expressed on T cells and NK cells and enriched on Tregs and 
other memory T cells, and increased in expression upon activation (Yu et al., 2009).  
 TIGIT is a relatively new co-IR to be recognized. Grogan and colleagues 
identified this novel member of the CD28 family using bioinformatics algorithms used to 
search for proteins expressed on T cells and NK cells that contained an immunoglobulin 
and ITIM domain (Yu et al., 2009). Using a large library of secreted proteins, the authors 
then identified TIGIT bound to the polio-virus receptor (PVR) with high affinity, 
suggesting PVR was the natural ligand for TIGIT. TIGIT also binds to PVRL2 (nectin-2), 
although with lower affinity than PVR (Anderson, Joller and Kuchroo, 2016).  
 Upon the binding of TIGIT to PVR, also known as CD155, phosphorylation of 
the cytoplasmic tail of TIGIT occurs and leads to the recruitment of SHIP1 which blocks 
the function of PI3K and MAPK, decreasing lymphocyte activation (M. Li et al., 2014). 
Similar to other co-IRs, ligation of TIGIT blocks T cell proliferation and effector 
function, but is different in that it actively inhibits apoptosis by increasing the survival 
factor Bcl-xL and the receptors for pro-survival cytokines IL-2, IL-7, and IL-15 
(Anderson, Joller and Kuchroo, 2016). While TIGIT’s role in blocking effector function 
by inhibiting pathways downstream TCR stimulation and cytokine signaling suggest it 
holds an important role in controlling immune responses. The promotion of cell survival 
makes it a potentially unique player in immune modulation. 
 TIGIT not only functions as a direct negative regulator of T cells and NK cells, it 
also acts to blunt immune responses by outcompeting the positive regulator CD226 
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(Lozano et al., 2017). CD226 promotes lymphocyte effector function through its 
association with the cell adhesion molecule LFA-1 (Shibuya et al., 2003). CD226’s 
binding to PVR and PVRL2 has been shown to promote this effector function, 
specifically cytokine secretion and cytotoxicity in CD8+ T cells and NK cells (Shibuya et 
al., 2003). When TIGIT is knocked down in vitro, blocking CD226 can recapitulate the 
phenotype of a system with a functional TIGIT that decreases effector function (Lozano 
et al., 2017). This indicates that some of TIGIT’s negative regulation of effector 
functions is because it outcompetes CD226’s binding to PVR.  
 The co-IR TIGIT also plays a unique role in specifically modulating TH2 function. 
TIGIT is upregulated on TH2 skewed T cells and blocking TIGIT decreases the 
production of TH2 cytokines IL-4 and IL-13, but not IFNγ (TH1) or IL-17 (TH17) 
(Kourepini et al., 2016). TIGIT is the most highly expressed on memory Tregs compared 
to other T cell subsets (Fleury et. al, 2017) and TIGIT positive Tregs potently suppress 
TH1 and TH17 responses, but are unable to regulate TH2 (Joller et al., 2014). While TH1 
and TH17 often drive pro-inflammatory responses, TH2 is often thought of as more pro-
fibrotic (Wynn, 2015). This role of TIGIT in controlling a pro-fibrotic phenotype is an 
attractive target in SSc due to fibrosis playing a major role in morbidity and mortality in 
these patients.  
 In vivo TIGIT is linked to autoimmune phenotypes and although TIGIT knockout 
mice do not spontaneously develop autoimmunity, autoimmune-prone systems are 
exacerbated by a lack of TIGIT (Anderson, Joller and Kuchroo, 2016). TIGIT -/- mice 
develop more severe EAE (Joller et al., 2011) as well as collagen induced arthritis (Levin 
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et al., 2011). This in vivo modulation of autoimmune functions in mice indicates that 
TIGIT may play a role in human disease.  
 Genetically the TIGIT-CD226 pathway has been connected to autoimmunity. 
GWAS studies have linked the gene for CD226 to both multiple sclerosis and type 1 
diabetes (Hafler et al., 2009). 
 The role of TIGIT in exhaustion has also begun to be explored. Like PD-1 and 
TIM-3 (Jones et al., 2008) TIGIT is increased on exhausted CD8+ T cells from HIV 
patients and the blockade of TIGIT in vitro can restore effector functions of exhausted 
cells (Chew et al., 2016). The efficacy of blocking TIGIT for cancer immunotherapy 
supports its role in modulating exhaustion. Tumor infiltrating T cells have been found to 
have high levels of TIGIT and PD-1 supporting the idea of exhausted cells in the tumor 
microenvironment (Johnston et al., 2014). Mice injected with colorectal cancer cells had 
a much higher level of survival if the mice were treated with both blocking antibodies to 
PD-1 and TIGIT compared with PD-1 alone (Johnston et al., 2014). Clinical trials 
exploring combination therapy of PD-1 and TIGIT are ongoing (NCT02913313).  
 TIGIT’s control of immune responses plays an important role in mediating 
immune exhaustion and regulating effector functions. The synergistic effect of blocking 
both PD-1 and TIGIT in increasing an anti-tumor response speaks to a non-redundant 
role of TIGIT in regulating exhaustion and TIGIT’s role in controlling TH2 responses 
suggests a potential role in regulating fibrosis. This makes TIGIT a potentially important 
player in the fibrotic disease of systemic sclerosis.  
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TIM-3 
 TIM-3 is a co-IR originally described as a marker for TH1 cells (Monney et al., 
2002), but was later discovered to be expressed at the highest levels on NK cells 
(Khademi et al., 2004). This co-IR also plays a role in decreasing lymphocyte function as 
well as being a marker of exhaustion, similar to PD-1 and TIGIT (Anderson, Joller and 
Kuchroo, 2016), but its unique expression profile and importance in controlling TH1 
based inflammation gives it its own biological niche.  
 The discovery of TIM-3 came from an exploration of markers specific for CD4+ 
TH1 cells and CD8+ Tc1 cells.  A receptor identified on TH1 cells was identified as T cell 
immunoglobulin and mucin domain containing molecule or TIM-3 that was functionally 
involved in controlling TH1 responses in vivo (Monney et al., 2002). Follow up studies 
showed that although TH1 and Tc1 cells expressed TIM-3, although as previously stated 
the cell type with the highest level of expression was natural killer cells (Khademi et al., 
2004) suggesting a potentially important role in modulating not only adaptive immune 
responses, but innate ones as well. 
 There are multiple ligands that have been reported to bind to TIM-3. Galectin-9 
(Gal-9) is the best characterized of these ligands. In vitro data shows that Gal-9 induces 
cell death in a TIM-3-dependent manner and in vivo Gal-9 decreases IFNγ production 
(Zhu et al., 2005). Gal-9 has also been shown to decrease the function of NK cells by 
decreasing cytotoxicity (Sun et al., 2016).  The molecules phosphatidylserine, high 
mobility group protein B1 (HMGB1), and Ceacam-1 have all also been reported to bind 
to TIM-3 (Anderson, Joller and Kuchroo, 2016).  
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 Signaling through TIM-3 is mediated by Bat3. When Gal-9 is not bound to TIM-
3, Bat3 remains localized on the cytoplasmic tail of TIM-3 and a catalytically active Lck 
is recruited to Bat3, leading to increased T cell activation. Cells that lack Bat3 have 
elevated levels of catalytically inactive Lck and T cell activation is decreased 
(Rangachari et al., 2012). Multiple different molecules involved in TCR signaling 
potentially bind to the cytoplasmic tail of TIM-3 as well, as previously mentioned, 
multiple ligands that bind to the extracellular domain. This leaves open the possibility of 
a much more complex signaling pathway of TIM-3 that is both ligand and intracellular 
modulator dependent (Anderson, Joller and Kuchroo, 2016).  
 Not only is TIM-3 a marker of a TH1 phenotype, it also potently regulates TH1 
function. The addition of TIM-3-Ig, which presumably competes for ligands with cell 
bound TIM-3, causes the hyperproliferation of TH1 cells in vivo (Sabatos et al., 2003). 
Blocking TIM-3 in a TH1-driven disease model, EAE, induces worse disease outcome 
(Monney et al., 2002). The addition of antibodies that block TIM-3 in a Treg suppression 
assay restore IFN-γ production to levels seen without suppressive Tregs, but it is unclear 
if this is just due to a defect in Treg suppression itself which is also decreased by a 
blockade of TIM-3 (Wang et al., 2009). The role of TIM-3 in the in vivo responses could 
partially be due to the role of NK cells. NK cells are the highest expressers of TIM-3 
(Khademi et al., 2004) and also produce large amounts of the TH1cytokine IFN-γ 
(Cooper, 2001). The role of TIM-3 in controlling the pro-inflammatory TH1 immune 
response gives it a unique role as a co-IR in modulating inflammatory settings. 
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 While no autoimmune phenotype has been reported in TIM-3 knockout mice, 
TIM-3 regulates autoimmune disease in disease-prone models (Anderson, Joller and 
Kuchroo, 2016).  As previously stated TIM-3 was originally reported to protect against 
EAE with antibodies blocking TIM-3 increasing EAE severity (Monney et al., 2002). 
TIM-3 can also regulate spontaneous autoimmune phenotypes in NOD mice experiencing 
accelerated disease upon the blockade of TIM-3 (Sánchez-Fueyo et al., 2003). This 
cements TIM-3 as an important co-IR to potentially play an important role in 
autoimmune diseases.  
 TIM-3, like other co-IRs, is a significant player in immune exhaustion in both 
mice and people. As previously stated, LCMV co-expression of PD-1 and TIM-3 on 
CD8+ T cells marked more exhausted cells (Jin et al., 2010). In patients with HIV, TIM-
3 expression was elevated and TIM-3+ cells responded less to HIV antigen-specific 
stimulation (Jones et al., 2008).  
 This exhaustion again manifests itself in cancer and TIM-3 is a potentially 
important target in the immuno-oncology field. In mouse tumor models the combination 
therapy of anti-PD-1 and anti-TIM-3 achieved better responses than one co-IR blockade 
along (Baumeister et al., 2016). This again shows the utility of targeting multiple co-IRs 
to modulate an exhaustion phenotype.  
 The role of TIM-3 in modulating immune function is similar to multiple other co-
IRs in its role of blocking effector function and marking an exhaustion phenotype in 
lymphocytes. It is important to remember, however, that this inhibitory molecule plays a 
non-redundant role in vivo, with its control of a TH1 response in EAE and its role in 
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controlling both adaptive and innate immune responses making it an important tool in 
controlling immune responses.  
 
LAG-3 
 Lymphocyte Activation Gene 3 (LAG-3) is another one of a long list of co-IRs 
that regulate immune responses. Like others, it has clinical implications for both 
autoimmunity and cancer and directly impacts lymphocyte function.  
 LAG-3 was originally discovered after being mapped to RNA transcripts 
produced in an NK cell line and confirmed in T cell lines. Like other co-IRs discovered 
later, Hercend and colleagues determined that resting lymphocytes do not express LAG-3 
but it is upregulated upon activation (Triebel et al., 1990). LAG-3’s structure is similar to 
that of CD4 and LAG-3 binds to MHC class II ligands similarly to CD4, but with even 
higher affinity. This means LAG-3 can outcompete CD4 to bind to class II, thus 
inhibiting CD4 T cell function (Huard et al., 1995).  
 Similar to the co-IRs, CTLA-4 and TIGIT, LAG-3 not only functions to inhibit 
immune responses by acting to outcompete the binding of molecules important for 
activation, but it also has its own signaling that effects function. LAG-3 function 
decreases CD3 dependent calcium influx, decreasing T cell activation (Hannier et al., 
1998). LAG-3 signaling is at least partially controlled by the intracellular KIEELE motif, 
and cells that express LAG-3 lacking a functional KIEELE motif proliferate at a higher 
rate than those that have a fully functional LAG-3 molecule (Workman and Vignali, 
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2005). LAG-3 signaling has predominantly been explored in the role of controlling T cell 
proliferation displaying its key role in T cell function and activation. 
 LAG-3’s role in T cell function makes it an important player in autoimmunity. 
LAG-3 deficiency alone does not predispose mice to autoimmunity, but like TIGIT and 
TIM-3, it can accelerate and worsen autoimmune phenotypes in established autoimmune 
models. Similar to TIM-3 knockout mice, NOD mice lacking LAG-3 have accelerated 
diabetes (Okazaki et al., 2011). 
 In the cancer field, LAG-3 has been identified as a potent regulator of immune 
function. Tumor infiltrating lymphocytes from ovarian cancer have high levels of LAG-3 
expression as well as decreased effector function that was partially reversed with the 
blockade of LAG-3 (Matsuzaki et al., 2010). Murine models of tumor growth can be 
modulated by the blockade of LAG-3 in combination with a blockade of PD-1 (Woo et 
al., 2012).  
 LAG-3 is expressed at very low levels in circulating lymphocytes (Fleury, et.al. 
2017). Despite its low expression at basal levels in the blood, it plays a crucial part in 
controlling immune responses in lymphoid and peripheral tissues as shown by its potent 
control of T cell proliferation and its role in modulating an autoimmune phenotype. This 
makes it an attractive target in the study of autoimmune dysfunction.  
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Co-Inhibitory Receptors in Human Autoimmune Diseases 
 While it has been well established that co-IRs can modulate autoimmune 
phenotypes in animal models, the role of co-IRs direct effects on human autoimmune 
diseases is still being explored. Changes in co-IR expression have been reported in 
autoimmune diseases, but a more concerted effort to characterize the receptors in vivo is 
still needed. 
 PD-1 is known to be a potent controller of immune responses in autoimmune 
animal models (Monney et al., 2002; Okazaki et al., 2011) and has been explored in 
multiple human autoimmune diseases. PD-1 expression has been reported to be increased 
on the T cells in lupus, but the authors were unable to significantly modulate the function 
of lupus PBMCs in vitro, compared to healthy donors, by blocking PD-1 (Liu, Weng and 
Weng, 2009). PD-1 is also increased on T cells in the synovial fluid of rheumatoid 
arthritis patients. However, soluble PD-1 was also increased and capable of inhibiting 
PD-1 mediated decreased T cell function, counteracting membrane bound PD-1’s anti-
inflammatory effects (Wan et al., 2006). Also of note, one ligand for PD-1, PDL-1, is 
expressed at increased levels on colonic epithelial cells from patients with inflammatory 
bowel disease (Nakazawa et al., 2004). 
 Other co-IRs have also been explored in autoimmune diseases. TIGIT is increased 
on CD4+ T cells in RA (Luo, Ye, et al., 2017) and SLE patients (Luo, Deng, et al., 2017) 
and its increased levels correlate with disease severity. TIM-3 is decreased on T cells 
from the cerebrospinal fluid of MS patients (Koguchi et al., 2006).  
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 In vivo, co-IRs have a role in controlling autoimmunity. An emerging 
phenomenon in patients treated with co-IR blockades in cancer is the appearance of 
autoimmunity after treatment (June, Warshauer and Bluestone, 2017). Patients treated 
with blocking antibodies to PD-1 are at risk for a large number of autoimmune 
manifestations from non-life threatening vitiligo in the skin to more serious colitis, 
hepatitis, and pancreatitis (Michot et al., 2016). Given the role of co-IRs in protecting 
from autoimmune phenotypes in mice, it is not surprising that blocking these receptors in 
humans could manifest in immune related adverse events (IRAEs). 
 Co-IRs play an important role in modulating immune responses and protecting 
against autoimmunity. This makes them significant to study in human autoimmune 
diseases in order to better understand their role in controlling harmful inflammation that 
can lead to increased morbidity and mortality. 
 
Co-Inhibitory Receptors in Systemic Sclerosis 
 The role of co-IRs in SSc pathogenesis is just beginning to be explored. In vivo 
modulation in animal models and the quantification of receptors in humans show that co-
IRs may play a role in controlling and modulating the disease. 
 As previously described, sclGvHD mice present a phenotype similar to human 
and in vivo data shows that co-IR regulation can have a role in disease pathogenesis. 
During the development of sclGvHD PD-1 is upregulated on T cells in the spleen and 
lymph nodes of mice that develop GvHD. If the donor cells used to induce sclGvHD lack 
PD-1, more mice succumb to the disease, therefore supporting the role of PD-1 as a 
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protector against a worse disease outcome. The addition of a PD-1 agonist has the reverse 
effect with the disease improving upon the activation of the PD-1 receptor (Fujiwara et 
al., 2014). This proof of concept in an animal model of SSc shows that PD-1 could have a 
protective role in SSc. 
 Some co-IRs have been explored in human SSc itself. Both membrane bound and 
soluble PD-1 have been reported to be increased in SSc (Fukasawa et al., 2017). CD226 
which as previously discussed, is an activation receptor sharing ligands with TIGIT, is 
increased in CD8+ cells in systemic sclerosis and its expression is correlated with severe 
skin disease and lung involvement (Ayano et al., 2015). TIM-3 has also been reported to 
be altered in SSc with higher levels of soluble TIM-3 in patients with the diffuse form of 
the disease (Chiba et al., 2017). 
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Figure 2. Exhaustion and Co-IR expression   
As lymphocyte function decreases, cells become exhausted. Exhaustion is defined by 
cytokine production and cytotoxicity decreases along with loss of proliferative potential. 
This corresponds to an increase in co-IR expression and the apoptosis of exhausted cells. 
 
 
 
 
 30 
 
Specific Aims and Hypothesis 
As previously stated, Systemic Sclerosis is an autoimmune connective tissue 
disorder. Descriptions of autoantibody production (Van Den Hoogen et al., 2013), 
increased pro-fibrotic cytokine production (Riccieri et al., 2003), and patients that have 
inflammatory signatures in their skin (Whitfield et al., 2003) all point to immune 
dysfunction in these patients. A better understanding of this dysfunction and how it 
affects disease pathogenesis is key to understanding and treating the disease. In 
particular, we focused on co-IRs which are known to be important regulators of the 
immune response and their loss in vivo often leads to increased autoimmune disease 
(Ansari et al., 2003; Anderson, Joller and Kuchroo, 2016). These receptors are also often 
found to be increased in chronic inflammatory environments and have an effect on 
dampening the immune response (Barber et al., 2006; Day et al., 2006). Given that SSc is 
an autoimmune disease with documented chronic inflammation (York et al., 2007) 
understanding the role of co-IRs in particular is of interest for understanding immune 
dysfunction in SSc. We hypothesized that chronic inflammation in systemic sclerosis 
leads to an increase in immune cell exhaustion and modulated regulation of the 
immune response. Our laboratory focused on documenting the expression of co-IRs on 
multiple lymphocyte populations in the blood of SSc patients. We used a 16 color flow 
cytometry panel to identify 10 separate lymphocyte populations and any changes in the 
expression of 4 different co-IRs on the surface of these lymphocytes. This large flow 
cytometry panel allowed us to identify any increases in co-IRs in SSc patients versus HCs 
in order to have a comprehensive view of the landscape of co-IR expression across 
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multiple cell types in circulation. In order to understand whether changes in co-IR 
expression have a role in modulating an immune response in SSc, we utilized an in vitro 
culture system to modulate co-IR function. Using blocking antibodies to co-IRs, we 
documented lymphocyte function by measuring soluble factors produced by the 
lymphocytes directly as well as how the soluble factors modulated by co-IR blockade 
effected SSc fibroblasts, a pathogenic cell type in SSc. The role of these receptors in 
controlling in vivo responses was explored using a mouse model of SSc treated with 
blocking antibodies to co-IRs. This dissertation is divided into three main research aims. 
In the first, we investigated changes in co-IR expression across multiple lymphocyte 
populations using both manual gating techniques and mathematical clustering to see 
differences in circulating lymphocytes between SSc and HCs. In the second aim, we 
examined defects in cellular function between PBMCs from SSc patients and how co-IRs 
play a role in this dysfunction. Finally, we used the animal model of sclGvHD to examine 
the role of these co-IRs in vivo.  
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CHAPTER TWO: MATERIALS AND METHODS 
 
Common Buffers and Solutions 
Phosphate Buffered Saline (PBS): pH 7.4 Potassium Phosphate monobasic (KH2PO4) 
1.06 mM, Sodium Chloride (NaCl) 155.17 mM, Sodium Phosphate dibasic (Na2HPO4-
7H2O) 2.97 mM Gibco® Life Technologies  
 
Complete Media (C10): RMPI 1640 Cell Culture Media with L-glutamine and phenol 
red, without HEPES Gibco® supplemented with 10% Fecal Bovine Serum (), 10mM 
HEPES (Gibco) 1 x MEM Non-essential amino acids (Gibco) 1mM Sodium Pyuvate 
(Gibco), 55nM 2-Mercaptoethanol (Gibco), and Pen-Strep 
 
FACs Staining Buffer: 1x PBS with 2% FBS 
 
Intracellular Fixation and Permeabilization Buffer set Thermo Fisher Scientific 
 
FoxP3 staining Buffer Set (eBioScience) 
 Fix/Perm Buffer (75% FixPerm Diluent, 25% FixPerm Concentrate) 
10x Permiablization Buffer (1x Perm buffer 10% 10x Perm Buffer 90% DI 
Water) 
 
1% Paraformaldahyde 
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2% Paraformaldahyde Diluted FACs Buffer 
 
 
Patients and Controls 
 All samples and clinical data were collected under a protocol approved by the 
Institutional review board at Boston University. Blood samples were obtained from 
patients in EDTA Blood Collection Tubes (BD Vacutainer®). Classification of patients 
was made according to ACR criteria (Van Den Hoogen et al., 2013). None of the patients 
were treated with immunosuppressive therapy within six months of blood draw. Patients 
and healthy controls were age matched.  
 
Sample Collection 
Blood samples were collected and PBMCs isolated the same day by under-laying 
LymphoprepTM (Stem Cell) under blood and separating PBMCs by density dependent 
centrifugation. PBMC samples were frozen in 50% RPMI media (10% FBS, 1% non-
essential amino acids, 1% HEPES, 1% PenStrep, 1% Sodium Pyruvate, 0.1% Beta-
mercaptoethanol) with 40% FBS and 10% DMSO and stored in liquid nitrogen.  
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Flow cytometric Analysis 
16 Color Phenotyping of Systemic Sclerosis and Systemic Lupus Erythematosus Blood 
 Frozen cells were thawed in a 37˚C water bath for 2 minutes. Cells were re-
suspended in C10 and centrifuged at 500 x g for 5 minutes at 4˚C. Supernatant was 
discarded and cells were again re-suspended in C10 media and centrifuged at 500 x g for 
5 more minutes at 4˚C. Cells were re-suspended in 1x PBS and spun again. Cells were re-
suspended PBS in the dark for 20 minutes at room temperature. Cell were washed with 
FACs buffer, pelleted, and re-suspend in FACS buffer containing 1:50 solution of 
FCγRIII and incubated in the dark at room temperature for 10 minutes. Add 
antibodystaining mix listed in table 2. Incubate for 30 minutes in the dark at room 
temperature. Wash with FACs buffer, pellet, and re-suspend in FACs buffer before 
running on FACSARIA SORP II the day of staining. 
 
Table 1. 16 Color Flow cytometric Panel for Co-IR Expression in SSc 
 Specificity Fluorochrome Ab clone Purpose 
1 γδ TCR BUV395 B1 γδ T cells 
2 CD127 BUV737 HIL-7R-M21 Tregs 
3 CD8 BUV805 SK1 Lineage 
4 PD-1 BV421 EH12.2H7 Exhaustion 
5 CD3 BV510 OKT3 T cell Lineage 
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6 CD16 FITC 3G8 NK cell Lineage 
7 CD45RO BV650 UCHL1 Memory 
8 CD56 BV786 NCAM16.2 NK cell linage/subsets 
9 CD25 BV605 BC96 Treg Lineage 
10 Vα24 TCR PE C-15 iNKT cell lineage 
11 LAG-3 PE-ef610 3DS223H Exhaustion 
12 TIGIT PE-ef710 MBSA43 Exhaustion 
13 Tim-3 PE-Cy7 F38-2E2 Exhaustion 
14 C1d Tetramer APC n/a iNKT lineage 
15 CD4 Af700 RPA-T4 Lineage 
16 CD14 APC-Cy7 HCD14 Monocyte Exclusion 
17 CD19 APC-Cy-7 HIB19 B cell exclusion 
18  NIR Zombie    
 
  
16 Color Phenotyping of Type 1 Diabetes Blood 
 Frozen cells were thawed in a 37˚C water bath for 2 minutes. Cells were re-
suspended in C10 and centrifuged at 500 x g for 5 minutes at 4˚C. Supernatant was 
discarded and cells were again re-suspended in C10 media and centrifuged at 500 x g for 
5 more minutes at 4˚C. Cells were re-suspended in 1x PBS and spun again. Cells were re-
suspended PBS containing Zombie NIR at no more than 1x106 cells/100 ul of Zombie-
NIR PBS and kept in the dark for 20 minutes at room temperature. Cell were washed 
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with FACs buffer, pelleted, and re-suspend in FACS buffer containing 1:50 solution of 
FCγRIII and incubated in the dark at room temperature for 10 minutes. Add antibody 
staining mix listed in table 2. Incubate for 30 minutes in the dark at room temperature. 
Wash with FACs buffer, pellet, and re-suspend in FACs buffer before running on 
FACSARIA SORP II the day of staining. 
 
Table 2. 16 Color Flowcytometric Panel for Co-IR Expression in T1D 
 Specificity Fluorochrome Ab clone Purpose 
1 γδ TCR BUV395 B1 γδ T cells 
2 CD127 BUV737 HIL-7R-M21 Tregs 
3 CD8 PerCp Cy5.5 SK1 Lineage 
4 PD-1 BV421 EH12.2H7 Exhaustion 
5 CD3 BV510 OKT3 T cell Lineage 
6 CD16 PE-CF594 3G8 NK cell Lineage 
7 CD25 BV605 BC96 Tregs Lineage 
8 CD56 FITC NCAM16.2 NK cell linage/subsets 
9 CD45RO BV650 UCHL1 Memory 
10 Vα24 TCR PE C-15 iNKT cell lineage 
11 LAG-3 Biotin 3DS223H Exhaustion 
12 CTLA-4 BV786 RUO Exhaustion 
13 Tim-3 PE-Cy7 F38-2E2 Exhaustion 
 37 
 
14 C1d Tetramer APC n/a iNKT lineage 
15 CD4 Af700 RPA-T4 Lineage 
16 CD14 APC-Cy7 HCD14 Monocyte Exclusion 
17 CD19 APC-Cy-7 HIB19 B cell exclusion 
18  NIR Zombie    
 
 
Detection of Cytokines using ELISA 
 All ELISAs were run using Affymetrix eBioScience Ready-Set-Go! ® Kits. 
ELISA plate was coated with 100μL/ well of 1 x capture antibody in 1 x Coating Buffer 
and incubated overnight at 4˚C. Wells were washed with 0.025% Tween in 1x PBS 3x. 
200μL of 1x ELISA/ELISPOT Diluent was added to wells and incubated at room 
temperature for 1 hour. Lyophilized standards were re-suspended in de-ionized water and 
left at room temperature for 15 minutes to dissolve. Wells were washed with 0.025% 
Tween in 1 x PBS 3x. Standard curve was prepared with 2-fold serial dilutions in 1x 
ELISA/ELISPOT Diluent in 100μL per well. 100μL of sample was added to wells and 
incubated at room temperature for 1 hour. Wells were washed with 0.025% Tween in 1 x 
PBS 3 times. 100μL of 1x Avidin-HRP diluted in 1x ELISA/ELISPOT Diluent was 
added to wells and incubated for 30 minutes at room temperature. Wells were washed 
with 0.025% Tween in 1 x PBS 6 times. 100μL of room temperature 1x TMB solution 
was added to each well. When standard curve turns blue add 100μL of 0.16 M H2SO4. 
Plate was read at 450nm on machine name.  
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Tissue Culture 
T cell Stimulation 
Frozen cells were thawed in a 37˚C water bath for 2 minutes. Cells were re-
suspended in C10 and centrifuged at 500 x g for 5 minutes at 4˚C. Supernatant was 
discarded and cells were again re-suspended in C10 media and centrifuged at 500 x g for 
5 more minutes at 4˚C. 5 x 105 cells and 8 x 105  Dynabeads® were added to a 96 well 
plate with 200μL of C10 media and incubated at 37˚C and after 72 hours 100μL of C10 
media was added to the wells. After an additional 24 hours, supernatants were collected 
and frozen at -80˚C. Supernatants were thawed and cytokines were detected using ELISA 
Ready-Set-Go!®  IFNγ, IL-10, and IL-17A for human.  
 
Natural Killer Cell Cytotoxicity Assay 
Frozen cells were thawed in a 37˚C water bath for 2 minutes. Cells were re-
suspended in C10 and centrifuged at 500 x g for 5 minutes at 4˚C. Supernatant was 
discarded and cells were again re-suspended in C10 media and centrifuged at 500 x g for 
5 more minutes at 4˚C. Cells were washed in FACs buffer and spun again. Cells were re-
suspend in FACS buffer containing Human FcR Binding inhibitory (eBioScience) and 
incubated in the dark at 4˚C for 15 mins. Antibody mix was added with anti- CD3 
PerCPe710 (Clone OKT3), anti-CD16 PE (Clone 368), anti-CD56 BV421 (Clone 
NCAM162), anti-CD19 APCe780 (Clone H1B19), and anti-CD14 (Clone HCU14) and 
incubated at 4˚C for 30 minutes. Cells were washed with FACs buffer twice. Cells were 
sorted on the FACSARIA SORP II the day of staining based on CD14-, CD19-, CD3-, 
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CD56med, CD16+ cells. Target cell line 721.221 was thawed and counted. 721.221 cells 
were washed with 1x PBS. 721.221 cells were re-suspended at 10 x 106 cells/mL in 1x 
PBS and CFSE was added at 1μM. Cells were incubated at room temperature for 10 
minutes in the dark then quenched with an equal volume of FBS, vortexed and left at 
room temperature for 5 minutes in the dark. 721.221 cells were washed with C10 media 
and re-suspended in C10 media. Sorted NK cells were combined with 5 x 103 721.221 
target cells in a 96 well round bottom plate at a ratio of of 10:1, 5:1, and 1:1 NK:target in 
200μL of media. Plate was spun down and media was replaced with 100μL of media with 
1:250 of anti-CD107a APC (Clone A3H) and 1:1000 of monesin (eBioScience) and 
placed at 37˚C for 90 minutes. Cells were collected and washed with 1 x PBS and re-
suspended in 1 x PBS with 1:1000 Live-Dead UV455 (eBioScience). Cells were fixed 
with 1% PFA in 1x PBS and washed with FACs buffer and re-suspended in FACs buffer 
and run on BD LSRII. 
 
In vitro Stimulation of PBMCs with allogeneic monocyte-derived dendritic cells 
Monocyte derived dendritic cells (DCs) were produced after selection of CD14+ cells 
(Stem Cell Technologies) from PBMCs isolated from a Buffy Coat, using the 
manufacturer’s instructions. CD14+ monocytes were cultured for 5 days in 7.5 ng/ml IL-4 
(BD) and 20 ng/mL GMC-SF (Miltenyi Biotec). On day 4, 1 ng/ml of E. coli LPS (Sigma) 
was added to the cultures to mature the dendritic cells. Previously frozen PBMCs from 
patients and healthy controls were thawed and co-cultured with allogeneic DCs at 1:10 
DCs to PBMCs with 5 μg/ml of blocking antibodies: anti-PD-1 (Clone J116, eBioScience), 
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anti-TIGIT (Clone MBSA43, eBioScience), anti-TIM-3 (Clone F38-2E2, BioLegend), or 
Isotype control (Clone P3.6.2.8.1, eBioScience) in the presence of human Fc Block (BD). 
Cultures were kept at 37°C and 5% CO2 for 72 hours and supernatants were collected and 
stored at -80°C. 
 
In vitro Stimulation of PBMCs with autologous monocyte-derived dendritic cells 
PBMCs from patients and healthy controls were collected and half the cells were frozen 
and half were set aside for monocyte derived dendritic cells. DCs were produced after 
selection of CD14+ cells (Stem Cell Technologies) from PBMCs, using the manufacturer’s 
instructions. CD14+ monocytes were cultured for 5 days in 7.5 ng/ml IL-4 (BD) and 20 
ng/mL GMC-SF (Miltenyi Biotec). On day 4, 1 ng/ml of E. coli LPS (Sigma) was added 
to the cultures to mature the dendritic cells. Previously frozen PBMCs from patients and 
healthy controls were thawed and co-cultured with autologous DCs at 1:10 DCs to PBMCs 
with 5 μg/ml of blocking antibodies: anti-PD-1 (Clone J116, eBioScience), anti-TIGIT 
(Clone MBSA43, eBioScience), anti-TIM-3 (Clone F38-2E2, BioLegend), or Isotype 
control (Clone P3.6.2.8.1, eBioScience) in the presence of human Fc Block (BD). Cultures 
were kept at 37°C and 5% CO2 for 24 hours. Media on the cells was replaced with media 
with 20ng/mL of PMA and 0.5 μg/mL of ionomycin and cells were placed at 37˚C. After 
1 hour 1:1000 brefeldin A was added to the cultures and cells were placed at 37˚C for 3 
hours. Cells were collected and washed with 1x PBS and re-suspended in 1x PBS with 
1:1000 Zombie UV and left at 4˚C for 30 minutes. Cells were washed and re-suspend in 
FACS buffer containing Human FcR Binding inhibitory (eBioScience) and incubated in 
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the dark at 4˚C for 15 mins. Antibody mix was added with and stained with anti-CD4 
BV510 (Clone OKT4) and anti-CD8 PerCP (Clone 53-6.7) and placed at 4˚C for 30 
minutes. Cells were washed with FACs buffer and re-suspended in Fix/Perm overnight at 
4˚C. Cells were then washed with 1x Perm Buffer and re-suspended in 100μL of perm 
buffer with anti-FoxP3 PE (Clone PCH101), anti-IL-10 PE-Cy7 (Clone JES3-9D7), anti-
IL-13 BV421 (Clone JES10-5A2), anti-IFNγ APC e780 (Clone 4S.B3), and anti-IL-2 APC 
(Clone MQ1-17H12) and incubated at 4˚C for 30 mins. Cells were washed with 1x Perm 
Buffer and then washed and re-suspended in FACs buffer. Samples were run on the BD 
LSRII. 
 
Multiplex Cytokine Analysis 
Supernatants from in vitro stimulation cultures were analyzed using a 14-plex cytokine 
bead array kit (MILLIPLEXTM MAP Millipore Corporation, USA) on the Luminex 100 
platform to determine cytokine concentrations. Samples were run with help from the 
Boston University Analytical Core. A human TH17 Magnetic Bead Panel 
(MILLIPLEXTM MAP HTH17MAG-14K-14) was used to detect concentrations of IFNγ, 
IL-10, IL-13, IL-22, IL-9, IL-33, IL-2, IL-21, IL-4, IL-23, IL-5, IL-6, IL-27, and TNFα. 
Data was analyzed using Milliplex Analysis 5.1 software. The standard curve was 
determined by interpolation from corresponding standards. IL-22 and IL-33 were excluded 
from analysis due to being below the limit of detection. Undetectable values were given an 
arbitrary value of 0. Values were clustered using Gene Cluster 3.0 and normalized, mean 
centered, and clustered by complete linkage followed by visualization in JavaTree. 
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Fibroblast Cell Culture 
  SSc human dermal fibroblasts were grown to 80% confluence in DMEM with 10% 
FBS.  2.5 x 105 cells were serum-starved with media with 0.5% FBS overnight. Next, media 
was replaced with 50% supernatant from in vitro stimulated PBMC cultures and 50% 
RPMI with 10% FBS. Additional control cultures were set up with 10 ng/ ml TGFβ1 
(R&D), 30 ng/ml IL-13 (R&D), or no cytokines. Cells were incubated for 24 hours at 37°C, 
washed with PBS and lysed with RLT (Qiagen). RNA was collected with an RNeasy® 
Mini Kit (Qiagen).  
 
Nanostring 
100 ng of RNA was added to NanoString polymerase chain reaction tubes. 20 μl of 
Reporter CodeSet diluted in Buffer CodeSet and 5μl of Capture ProbeSet reagent 
(NanoString Technologies) was added to RNA. Sample was placed in MJ Mini 
thermocycler (BioRad) at 67˚C. Samples were then moved and processed in nCounter Prep 
Station (NanoString Technologies). Genes were normalized to a list of housekeeping 
genes, following a method previously described (Rice 2015). Values were clustered using 
Gene Cluster 3.0 and normalized, mean centered, and clustered by complete linkage 
followed by visualization in JavaTree. 
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SclGvHD treated with anti-TIGIT and anti-TIM-3 
Spleens from B10.D2 and Balb/c mice were collected crushed on a 40 μm nylon filter 
and washed with FACs buffer. Red blood cells were lysed with ACK lysis buffer at room 
temperature for 3 minutes. Cells were washed twice with FACS buffer. Cells were re-
suspended in media at 100 x 106 splenocytes per 1mL of C10 media with 1 unit of 
heparin. Cells were filtered through a 40 μM nylon filter and 30 x 106 cells were injected 
via tail vein in Rag2-/- Balb/c mice. Mice were treated with IgG1 Isotype (clone MOPC-
21), IgG2A Isotype (clone 2A3), anti-TIM-3 (clone RMT3-23), or anti-TIGIT (clone 
IG9) every 2 days 1 week after initiation of sclGvHD. Mice were weighed and scored 
twice weekly for up to 4 weeks.  
 
Table 3. SclGvHD Grading System 
 0 1 2 
Fur Smooth Fur Rough Fur with 
some Fur loss 
Large clumps of 
missing fur 
Skin No red Some red/scaling Red scaly skin 
Activity Active Slightly Lethargic Very Lethargic 
Posture No Hunch Moderately 
Hunched 
Severe Hunch 
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Mathematical modeling 
Partial least squares discriminant analysis (PLSDA) was conducted in MATLAB 
using the PLS_Toolbox (Eigenvector Research, Inc.). Data was normalized along each 
parameter by Z-score before application of the algorithm. Cytokines or genes with non-
zero values in fewer than half of subjects, were excluded from analysis. Cross-validation 
was performed with one-fifth of the relevant dataset, and the number of latent variables 
(LVs) was chosen to minimize cross-validation error. Model confidence was calculated by 
randomly permuting the response variables 100 times and rebuilding the model to form a 
distribution of error for random models, and comparing our model to this distribution with 
the Mann-Whitney U test. Importance of each parameter to the model prediction was 
quantified using variable importance in projection (VIP) score. A VIP score greater than 1 
(above average contribution) was considered important for model performance and 
prediction. 
The LASSO method was applied for variable selection in the gene expression data 
to determine the minimum gene set necessary for distinguishing treatment groups (Matlab, 
Mathworks). K-fold cross-validation was utilized to optimize the set of gene parameters 
such that the error of the resulting model was minimized. 
 
Statistical analysis 
T tests were performed using the R function t.test with correction for multiple 
comparisons made with the R function p.adjust using the fdr parameter for false discovery 
rate. 
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CHAPTER THREE: FLOW CYTOMETRIC ANALYSIS OF SYSTEMIC 
SCLEROSIS PBMCS SHOWS CHANGES IN CO-INHIBITORY RECEPTOR 
EXPRESSION 
 Parts of this chapter were originally published in: Fleury, M. Belkina, A. Proctor, 
E. Zammitti, C. Simms, R. Lauffenburger, D. Snyder-Cappione, J. Lafyatis, R. Dooms, 
H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors 
PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis, 
Arthritis & Rheumatology.  https://doi.org/10.1002/art.40399 
 
Rationale 
The function of T cells and NK cells is regulated by co-inhibitory receptors (co-
IRs) such as PD-1, LAG-3, TIGIT, and TIM-3 (Ferris, Lu and Kane, 2014; Anderson, 
Joller and Kuchroo, 2016). Engagement of these receptors by their ligands limits cytokine 
production in response to TCR or activating NK receptor stimulation. Co-IRs hence play 
critical physiological roles in limiting tissue damage from excessive immune activation. 
However, chronically increased expression of multiple co-IRs is a hallmark of immune 
exhaustion (Wherry, 2011), where immune cells are no longer able to execute effector 
functions to fight chronic viral infections and cancer (Day et al., 2006; McKinney et al., 
2015). In autoimmunity, co-IRs are protective: antibody blockade or genetic deletion of 
PD-1, TIM-3, TIGIT and LAG-3 in mouse models of autoimmune diseases such as type 1 
diabetes, lupus and multiple sclerosis all result in accelerated or exacerbated disease 
(Anderson, Joller and Kuchroo, 2016). Treatment of cancer patients with co-IR blockade 
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often precipitates autoimmune adverse events (June, Warshauer and Bluestone, 2017). As 
a corollary, reinforcing immune checkpoints in autoimmune disease may have 
therapeutic benefit. In support of this, an exhaustion-like phenotype marked by an 
increase in co-IR expression correlated with less flares in lupus patients (McKinney et 
al., 2015), while the presence of TIM-3+ T cells was associated with milder forms of 
multiple sclerosis (Saresella et al., 2014). In SSc, a recent report indicates that the PD-1 
pathway is involved in regulating disease severity (Fukasawa et al., 2017).    
Understanding the role of co-IRs in systemic sclerosis begins with documenting 
any changes in the expression of these receptors in patients to gain insight into potentially 
altered expression of these receptors in patients.  
Results 
3.1 Patient Parameters 
Patients were recruited to the study if they met the ACR diagnostic criteria (Van 
Den Hoogen et al., 2013) and had not taken any immune-modulatory drugs for at least 6 
months. Healthy controls were aged matched to the patient population. PBMCs were 
collected from the blood of patients and healthy controls and stored at liquid nitrogen and 
thawed the day of staining to quantify co-IR expression. Both dSSc and lSSc patients 
were collected as well as patients with lung disease involvement including ILD and PAH. 
There was a large range of reported skin scores, but most patients were diagnosed as lSSc 
with a very low MRSS. The low skin score even among the dSSc patients could be due to 
our stringent criteria of only taking patients not on immuno-modulatory drugs since 
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standard of care for high MRSS is methotrexate (Walker and Pope, 2012). The patients 
and healthy controls were predominantly white with a large variety of disease duration 
from months to years. Patients in our cohort were predominantly female, which matches 
with reports that SSc predominantly effects women (Van Den Hoogen et al., 2013). 
 
Table 4. Clinical Features of Systemic Sclerosis Patients and Healthy Controls 
Characteristic    HC   SSc 
     n=19   n=28 
Sex, number males/females  8/11   1/27 
Age           52 (25-69)           57 (32-68) 
Age of Onset, median   NA            46 (24-74) 
Disease Duration    NA   7.3 years (1 month – 42 years) 
Race, Hispanic-White/Black/White 0/1/18   2/0/26 
Number dSSc/lSSc   NA   6/22 
Modified Rodnan Skin Score  NA   5 (0-36)* 
Lungs 
 ILD    NA   9 
 PAH    NA   10 
       *7 patients no MRSS reported 
 
3.2 Characterization of PBMCs in SSc show a maintenance of lymphocyte population 
percentages, with the exception of an increase in circulating Tregs 
Using a 16-color flow cytometry panel specifically designed to quantify co-IRs on 
T cells and NK cells we identified immune cell subsets in SSc PBMCs (Belkina and 
Snyder-Cappione, 2017). Twelve distinct immune cell types could be identified using an 
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automated viSNE algorithm to blindly cluster cell subsets using fluorescence data to 
reduce any bias. A T cell subset that was CD8+ was identified as well as CD4+ cluster, 
and Tregs clustered separately within the CD4+ group. Other T cell subsets 
independently clustered with γδ TCR+ cells, and iNKT cells forming distinct clusters. 
NK cell subsets were also identified with CD56hiCD16- and CD16+CD56- populations 
being identified. Clustering also separated out a group of CD56-CD16med cells that 
expressed CD45RO. Within the CD4+ and CD8+ clusters there was separation of 
memory CD45RO+ cells and non-memory CD45RO- cells.  (Figure 3).  
We also used a more traditional manual gating strategy. After exclusion of dead 
cells as well as CD19+ B cells and CD14+ monocytes, CD3+ T cells were further divided 
in CD4+CD8- T helper cells, CD4-CD8+ cytotoxic T cells, γδ T cells, and iNKT cells. 
Within the CD4+ T cells, regulatory T cells (Tregs) were separated from conventional T 
cells (Tconv) based on high expression levels of CD25 and low levels of CD127. CD4+ 
and CD8+ T cell subsets were subdivided into CD45RO+ memory and CD45RO- naive 
subsets (Rothstein et al., 1991) (Figure 4). Gating of co-IRs was set on negative controls 
(Figure 5). It is important to note here that we did not observe any differences in the 
frequencies of the major T cell types between the SSc and healthy control groups (Figure 
6A), except for an increase in CD25+CD127- Tregs in the SSc group (Figure 6B).  
Interestingly, Tregs from SSc patients showed a reduction of cells with a CD45RO+ 
memory phenotype (Figure 6C).  
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Figure 3. ViSNE clustering of Cell Types in PBMCs. 
Single live CD19-CD14- events were gated from flow cytometry data of a representative 
subject and t-SNE dimension reduction was applied with lineage marker channels used 
for clustering. 
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Figure 4. Gating strategy for Analysis of co-IR Expression in Immune cell Subsets 
from Patient PBMCs 
PBMCs were isolated from 28 SSc patients and 19 age-matched controls. The cells were 
stained with a 16-color antibody panel for flow cytometric analysis of immune cell 
subsets and co-IR expression. Flow cytometry data were manually gated as follows: (A) 
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Cells were first gated on forward and side scatter to select for lymphocytes, then gated on 
height versus area followed by width versus height to gate out doublets. Cells were then 
gated on Red A-A negative to gate out dead cells, CD14+ monocytes and CD19+ B cells. 
(B) Live non-B cell lymphocytes were gated into CD3+ and CD3- fractions. The CD3+ 
fraction was gated multiple ways: CD4+ and CD8+ T cells, Vα24+ and CD1d tetramer+ 
(iNKT cells) and γδ TCR+ (γδ T cells). Within the CD4+ gate, Tregs were gated as 
CD25hiCD127lo and the CD25lo fraction was designated conventional T cells (Tconv). (C) 
CD4+ and CD8+ T cell fractions were further separated in CD45RO+ (effector/memory) 
and CD45RO- (naïve) subsets. 
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Figure 5. Gating strategy to determine co-IR-positive cells 
PD-1, TIGIT, TIM-3 and LAG-3 were gated based on Fluorescence Minus One (FMO) 
samples in which antibodies to individual co-IRs were left out. Dot plots show PD-1 (A), 
TIGIT (B), TIM-3 (C) and LAG-3 (D) gating compared to the corresponding FMO 
sample. 
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Figure 6. Frequencies of T cell subsets in SSc patients compared to Healthy Controls 
Frequency of lymphocyte subsets identified by manual gating as described in Figure 4 
was compared between SSc patients and healthy controls. Graphs show (A) percentages 
of CD4+, CD8+, γδ TCR+, and iNKT cells within the CD3+ gate +/- SEM, (B) 
percentage of CD25hi CD127lo Tregs within the CD4+ gate. +/- SEM, (C) percentages of 
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CD45RO+ memory cells within each T cell type +/- SEM. Each symbol represents an 
individual subject. Statistics was done with t test * p≤ 0.05. 
3.3 Co-IR expression is upregulated on specific cell types in SSc with PD-1 and 
TIGIT upregulated on some T cell populations, while TIM-3 is upregulated on NK cell 
subsets. 
  Within the viSNE clustering expression of the co-IRs PD-1, TIM-3, TIGIT and 
LAG-3 showed significant cell-type specificity with PD-1 mostly expressed in 
CD45RO+ memory T cells, TIGIT in T cells and NK cells and TIM-3 predominantly in 
NK cells (Figure 7). LAG-3 showed an overall low expression.  
To compare co-IR expression on blood lymphocyte subsets from SSc patients we 
identified co-IR positive cells using our manual gating strategy to allow for the definition 
of co-IR positive and negative cells, something not identified in viSNE. For CD4+ Tconv 
cells, CD4+ Tregs, and CD8+ T cells, PD-1, TIGIT, TIM-3 and LAG-3 expression was 
determined within the CD45RO+ effector/memory population, since naïve T cells 
typically express low levels of these receptors. In SSc patients, the number of PD-1-
expressing cells within the CD4+ Tregs and γδ T cells were increased compared to 
healthy subjects, while no changes in PD-1 expression were observed on CD8+ T cells, 
iNKT cells, or NK cell subsets (Figure 8A). The difference in PD-1 expression on CD4+ 
Tconv cells did not reach statistical significance after a false discovery rate analysis, but 
strongly trended towards and increase (p = 0.054) (Figure 8A). TIGIT was enhanced on 
CD4+ Tconv, Tregs and CD8+ T cells from SSc patients, but not γδ T cells, iNKT cells, 
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and NK cells thus showing a somewhat different pattern than PD-1 (Figure 8B). TIM-3 
showed low expression levels on all T cell subsets, confirming viSNE analysis, and no 
changes between healthy controls and SSc patients (Figure 8C). As noted above, TIM-3 
was strongly present on NK cells and further increased on the CD16+CD56med subset in 
SSc patients. LAG-3 was minimally present on all analyzed subsets and there were no 
noteworthy changes between healthy subjects and SSc patients (Figure 8D). Not 
surprisingly, inhibitory receptors were less expressed in CD45RO- naive Tconv, Tregs, 
and CD8+; although we did observe an increase in PD-1 on CD45RO- Tregs and an 
increase in TIGIT on CD45RO- Tconv cells (Figure 9).  
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Figure 7. Expression of co-IRs on Distinct Cell types. 
t-SNE plots showing the expression of PD-1, TIGIT, TIM-3 and LAG-3 on immune cell 
subsets mapped as in Figure 3 (color scale depicts fluorescence intensity as a measure of 
expression level). 
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Figure 8. SSc Patients Express Increased levels of PD-1, TIGIT and TIM-3 in 
Defined peripheral blood lymphocyte subsets  
Using manual gating, the percentage of (A) PD-1+ (B), TIGIT+ (C), TIM-3+ (D), and 
LAG-3+ cells within CD4+CD25loCD45RO+ Tconv cells, 
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CD4+CD25hiCD127loCD45RO+ Tregs, CD8+CD45RO+ T cells, γδ TCR+ T cells, iNK 
T cells, CD16+CD56med NK cells, and CD16-CD56hi NK cells was determined. Each 
symbol represents an individual subject. Mean ± SEM is indicated. iNKT cells only 
shown if >20 events were recorded. Statistics was done with t test with false discovery 
rate adjustment * p≤ 0.05 
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Figure 9. Co-IR expression on CD45RO- T cell subsets 
Co-IR expression was determined on CD45RO- naive T cell subsets. (A-D) Percentages 
of LAG-3+ (A), PD-1+ (B), TIGIT+ (C) and TIM-3+ (D) cells within the CD45RO- gate 
of Tconv, Tregs, and CD8+ T cells +/- SEM. Statistics was done with t test * p≤ 0.05. 
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3.4 Increased co-expression of PD-1 and TIGIT on T cell populations. 
One hallmark of exhausted T cells is the accumulated expression of multiple co-
IRs on the surface (Wherry 2011). Comprehensive co-IR signature analysis revealed that 
CD4+ Tconv cells and Tregs from SSc patients contained an increased frequency of PD-
1+ TIGIT+ double positive cells, compared to healthy subjects (Figure 10 A-D). In NK 
CD56med cells, co-expression of TIGIT and TIM-3 showed a trend towards increased 
presence in SSc patients vs HCs (Figure 10 E-F).  The increased presence of T cells 
expressing combinations of co-IRs in SSc patients suggested an increased level of 
immune dysfunction and exhaustion in those patients and provided a strong rationale for 
investigating the functional role of co-IRs in the activation of T cells from SSc patients. 
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Figure 10.  SSc patients contain increased levels of PD-1+ TIGIT+ Double Positive T 
cells 
Co-expression of PD-1 and TIGIT on lymphocyte subsets form Fig. 1 was analyzed using 
manual gating. (A) Representative dot plots of PD-1+ TIGIT+ double positive cells in 
CD4+ Tconv cells of healthy controls (HC) and SSc patients (B) Graph shows 
percentages of PD-1+TIGIT+ Tconv cells from all subjects. (C) Representative dot plots 
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of PD-1+ TIGIT+ double positive Tregs in HC and SSc patients. (D) Graph shows 
percentages of PD-1+TIGIT+ Tregs from all subjects. (E) Representative dot plots of 
TIGIT TIM-3 double positive CD16+CD56med NK cells in HC and SSc patients. (D) 
Graph shows percentages of TIGIT TIM-3 double positive CD16+CD56med NK cells 
from all subjects ** p≤ 0.01 
 
3.5 Relationship between Tregs and co-IR expression levels 
Within our data set, the increase in circulating Tregs could be mostly attributed to 
the role of seven outlier patients that showed an increase. To determine if there was 
anything distinct about these patients, we examined the presence of significantly more 
Tregs that could not be attributed to SSc disease type (Limited versus Diffuse) or the 
presence or absence of lung and skin involvement (data not shown). Intriguingly, patients 
with high Treg percentages also had increased co-IR expression. PD-1 expression was 
higher on Tconv cells from SSc patients with high Tregs compared to those with normal 
levels. TIGIT was enhanced in both Tconv and Tregs and TIM-3 was also increased on 
CD16+CD56- NK cells from the same patients (Figure 11). This is suggestive of a more 
“activated” disease environment in these patients, leading to Treg expansion and 
enhanced co-IR expression.  
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Figure 11. Co-IR expression in SSc patients with high percentages of Tregs 
SSc patients were divided into those with high levels of Tregs and those with normal 
levels and co-IR expression on multiple T cell populations from these patients was 
compared. (A) Graph shows percentages of CD4+CD25hiCD127lo Tregs within CD4+ T 
cells. The blue box designates patients with normal levels of Tregs and the red box 
designates patients with high levels of Tregs. (B-E) The percentage of PD-1+ (B), 
TIGIT+ (C), TIM-3 (D) and LAG-3+ (E) cells within the indicated T and NK cells 
populations from Treghi vs Treglo patients +/- SEM. Each symbol represents an individual 
subject. Co-IR expression on iNKTs only graphed if >20 events were recorded. Statistics 
was done with t test * p≤ 0.05. 
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3.6  Co-IR expression and Disease states 
 SSc is a heterogenous and unpredictable disease (Van Den Hoogen et al., 2013). 
While skin and internal organ involvement is often a predictor of disease severity and 
progression, work has been done to use other biomarkers to better understand and treat 
disease outcomes (Whitfield et al., 2003; Lisa M Rice et al., 2015). In order to 
understand if co-IR expression had any correlation with the disease and could act as a 
biomarker, we compared patient clinical data with co-IR expression.  
 We first compared co-IR expression across different disease states. Patients in our 
cohort were classified as either lSSc or dSSc and we compared the co-IR expression 
between these two groups of patients. We did not find any statistically significant 
differences in co-IR expression between these patients (data not shown). SSc patients 
often progress to have lung disease so we compared co-IR expression between patients 
without lung involvement and those with either ILD or PAH. Patients with ILD had a 
statistically significant increase in the percentage of Tregs that expressed both PD-1 and 
TIGIT (Figure 12).  
 Co-IR expression did not correlate with disease duration, MRSS, or forced vital 
capacity (FVC) which is a read out of lung function (data not shown). While this was 
surprising, our patients had a very low skin score and few patients had reported FVC 
tests. Follow up studies with more patients with higher skin score and more patients with 
reported FVC could provide better insight into the potential role of co-IRs in disease 
severity.  
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Figure 12. PD-1 TIGIT Double Positive Tregs in patients with Lung Disease 
PBMCs were stained and gated based on the protocol outlined in Figure 4. SSc patients 
were divided into those with no lung involvement (NLI), those with ILD, those with 
PAH, and those with both ILD and PAH. The percentage of Tregs that were double 
positive for PD-1 and TIGIT were compared between healthy controls and patient subsets 
as well as NLI patients and those with lung involvement +/- SEM. Each symbol 
represents an individual subject. Statistics was done with t test * p≤ 0.05, * p≤ 0.01, and 
*** p≤ 0.001. 
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3.7 Co-IR expression in other autoimmune diseases 
 We were also able to compare co-IR levels in two other autoimmune diseases. 
SLE is a heterogeneous autoimmune disease that, like SSc, effects multiple organs in the 
body (Yu, Gershwin and Chang, 2014). Type 1 Diabetes (T1D) is an autoimmune disease 
where the insulin producing -cells in pancreatic islets are destroyed leading to 
hyperglycemia and a loss of blood sugar control (Atkinson, Eisenbarth and Michels, 
2014). The comparison of co-IR levels in these two diseases allowed us to determine if 
the upregulation of co-IRs in a controlled cell type-specific manner is found in 
autoimmunity in general, or speaks to a disease-specific response. 
 SLE patients did have an increase in co-IR expression. There was a general trend 
towards an increase in the expression of PD-1 and TIGIT on memory Tconv in SLE 
patients compared to healthy controls; although the difference did not maintain statistical 
significance after a false discovery rate analysis (Figure 13A). SLE memory Tregs did 
have a statistically significant increase in PD-1 expression compared with healthy 
controls, similar to SSc Tregs. Surprisingly, no increase in TIGIT was seen in SLE 
memory Tregs which was a strong finding in SSc memory Tregs (Figure 13B). No co-IR 
changes were seen on CD8+ T cells in SLE (Figure 13C). Also, like SSc, SLE 
CD16+CD56med NK cells had an increased expression of TIM-3 (Figure 14). The 
increase in certain co-IRs on specific cell types is intriguing, especially since only 5 SLE 
patients were compared to healthy controls. 
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 The observation of an increase in CD4+ cells that expressed both PD-1 and TIGIT 
in SSc PBMCs provides evidence for an increased state of exhaustion in circulating 
CD4+ T cells in Scleroderma patients. With a limited number of SLE patients, we only 
saw a significant increase in PD-1 on Tregs in SLE compared to HCs. However, a trend 
towards significance for PD-1 and TIGIT expression on Tconv cells suggests a similar 
potential state of exhaustion in a second systemic autoimmune disorder. 
 The observation of increased co-IRs was not seen in the organ-specific 
autoimmune disease T1D. No changes were seen in the percentage of co-IR expressing T 
or NK cells in these patients (data not shown). This suggests that the increased co-IR 
expression seen in SSc and SLE patients could be disease-specific. While some other 
autoimmune diseases such as Rheumatoid Arthritis (RA) (Wan et al., 2006) and SLE 
(Jiao et al., 2014) report increases in PD-1 specifically there is a need to better 
characterize which autoimmune diseases show changes in what co-IRs and what this 
could potentially mean for pathogenesis. 
 Our data describing autoimmune diseases outside of SSc is preliminary and 
should be further developed with larger study groups. Three of the five SLE patients we 
report were also diagnosed with SSc questioning whether the changes in co-IR expression 
were more driven by a systemic inflammatory disorder, or an SSc phenotype. Also, a 
different flow cytometry panel was used to look at co-IR expression on the T1D patients, 
not only does this not allow for a direct comparison between SSc, SLE, and T1D 
samples, it also means the co-IR TIGIT was not evaluated on T1D PBMCs.  
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 Figure 13. Co-IR Expression on CD45RO+ T cell subsets from SLE Patients 
PBMCs were stained with the 16 color flow cytometric panel for SSc and SLE. Gating 
was performed as shown in Figure 4. Co-IR expression was determined on CD45RO+ 
memory T cell subsets. Percentages of (A) % PD-1 and TIGIT + on memory Tconv (B)% 
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PD-1 and TIGIT + on memory Tregs (C) % PD-1 and TIGIT + on memory CD8+ +/- 
SEM. Statistics was done with t test * p≤ 0.05 corrected with a FDR 
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Figure 14. Increased TIM-3 Expression on NK Cells from SLE patients 
PBMCs were stained with the 16 color flow cytometric panel designed for SSc and SLE. 
Gating was performed as outlined in Figure 4. (A) Percentage of CD16-CD56hi NK cells 
that express TIM-3 (B) Percentage of CD16+CD56low NK cells that express TIM-3. 
Statistics was done with t test * p≤ 0.05 corrected with a FDR. 
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DISCUSSION 
 Co-IRs have been implicated to be important for the control of autoimmune 
responses, but the majority of these findings have been made in animal models of 
autoimmune diseases (Anderson, Joller and Kuchroo, 2016). The role of co-IRs in human 
clinical autoimmune disorders has begun to be studied (Francisco, Sage and Sharpe, 
2010; Jiao et al., 2014; Chiba et al., 2017), but our study is the first to comprehensively 
analyze multiple co-IRs across multiple cell types in SSc. 
 We found expression of co-IRs to be dysregulated in a cell-specific manner and 
not just as a broad upregulation of all co-IRs across multiple cell types. While PD-1 
upregulation was limited to CD4+ T cells, TIGIT was upregulated on both CD4+ and 
CD8+ T cells. Within the NK cell compartment it was the co-IR TIM-3 that was 
upregulated, and while TIGIT is highly expressed on NK cells, there was no increase in 
the expression of TIGIT on SSc NK cells compared to healthy controls. While three of 
the four co-IRs analyzed were found to be upregulated on distinct cell types, the fourth 
co-IR, LAG-3, was not found to have any changes in expression on any of the 
lymphocyte populations defined in this study. While all these co-IRs can be upregulated 
by inflammatory factors that lead to activation (Belkina and Snyder-Cappione, 2017), the 
aberrant expression of some, but not all co-IRs in a cell-specific manner suggests that the 
upregulation of these receptors is not just a marker of activation, but potentially a true 
marker of a complex level of immune exhaustion in these patients. 
 Roughly a third of the SSc patients were found to have high percentages of 
circulating Tregs within the CD4+ cell population. These outliers drove up the average 
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percentage of Tregs in SSc patients above that of healthy controls supporting previous 
reports of increased Tregs in SSc patients (Slobodin et al., 2010) and displays the 
heterogeneity of these patients. Donors who have more Tregs also have an enrichment of 
PD-1 and TIGIT on CD4+ T cells in circulation. This could indicate a more inflammatory 
environment in these patients. Increased immune activation is known to increase Treg 
numbers (Walker et al., 2003) as well as co-IR expression levels (Belkina and Snyder-
Cappione, 2017). Whitfield and colleagues have been exploring the heterogeneity of SSc 
using gene expression data from skin biopsies of patients and have found that a subset of 
patients have a much more inflammatory microenvironment (Pendergrass et al., 2012). 
The identification of a minority of patients with an inflammatory phenotype could 
correlate with an increase in Tregs in these patients. 
We also observed an increase in the percentage of PD-1 TIGIT double positive 
(DP) Tconv and Treg in patients with SSc. The increased expression of a two or more co-
IRs that are co-expressed on individual cells has been described to mark cells with an 
increased level of immune exhaustion (Wherry, 2011). This finding of increased DP 
CD4+ T cells in SSc patients may indicate an advanced state of exhaustion in these 
patients. Despite this increase in PD-1 and TIGIT DP cells, there was no increase in 
expression of TIM-3 or LAG-3 on T cells in SSc patients. We would hypothesize that a 
truly advanced state of exhaustion would be caused by an additive effect of multiple co-
IRs; whether the co-expression of TIGIT and PD-1 represents this state, or whether the 
lack of TIM-3 and LAG-3 expression in the T cell compartment indicates a less 
exhausted phenotype is not clear at this time. There are also a large number of other 
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reported co-IRs, including CD160 (Cai et al., 2008), 2B4 (McNerney, Lee and Kumar, 
2005) among others, that we did not quantify and so whether they provide an additional 
additive effect leading to increased exhaustion remains to be explored.  
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CHAPTER FOUR: FUNCTIONAL CHARACTERIZATION OF IMMUNE 
DYSFUNCTION IN SYSTEMIC SCLEROSIS 
 Parts of this chapter were originally published in: Fleury, M. Belkina, A. Proctor, 
E. Zammitti, C. Simms, R. Lauffenburger, D. Snyder-Cappione, J. Lafyatis, R. Dooms, 
H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors 
PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis, 
Arthritis & Rheumatology.  https://doi.org/10.1002/art.40399 
 
Rationale 
While changes in co-IR expression in SSc patients suggest a potential role in 
disease pathogenesis, functional data that would link co-IRs to immune dysfunction in 
SSc would provide stronger support for this hypothesis. Co-IRs have been reported to 
control immune responses both in vitro and in vivo (Freeman et al., 2000; Fujiwara et al., 
2014) so their role in controlling aberrant immune responses in SSc could be an 
important mechanism in disease pathogenesis.  
In vitro it has been shown that lymphocyte function can be mediated by co-IRs. 
The interaction of PD-1 with its ligands PDL-1 (Freeman et al., 2000) and PDL-2 
(Latchman et al., 2001) has been shown to decrease the activation and proliferation of T 
cells in vitro. TIGIT (Lozano et al., 2017), TIM-3 (Gleason et al., 2012), and LAG-3 
(Matsuzaki et al., 2010) have all also been shown to decrease the proliferation and 
production of cytokines by lymphocytes in vitro. This potent regulation of immune 
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responses in human lymphocytes indicates that co-IR function can be important for 
immune cell function. 
These receptors have also been shown to be important in regulating immune 
responses in in vivo models. Knockout mice that lack co-IRs have worse autoimmunity in 
autoimmune models of disease (Okazaki et al., 2011; Fujiwara et al., 2014) indicating 
these receptors are important for controlling immune responses against self. The blockade 
of these receptors with antibodies in these in vivo models also have similar results in 
perpetuating autoimmunity (Salama et al., 2003; Fujiwara et al., 2014) showing these 
receptors’ functions can be modulated in vivo to regulate autoimmune responses. 
Advanced states of exhaustion are not only represented by a decrease in effector 
function and an increase in co-IR expression, but also in an epigenetically modified state 
that is refractory to re-establishment of effector function even upon co-IR blockade 
(Ghoneim et al., 2017). This becomes problematic in cancer where only a minority of 
patients treated with co-IR blocking therapy retain long term remission (Topalian et al., 
2014).  
The potency of co-IRs in regulating lymphocyte function shows they are not just 
markers of immune dysregulation, but play an important role in immune cell function. 
Understanding to what extent these receptors are involved in regulating immune cells in 
SSc is a necessary step in understanding the role of the immune system in a disease with 
a poor prognosis and few treatment options. 
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RESULTS 
4.1 T cells show Features of Exhaustion 
 T cells were activated using a two-signal mechanism of TCR activation and co-
stimulation (Lenschow, Walunas and Bluestone, 1996). Ligation and crosslinking of CD3 
and CD28 on T cells provides a surrogate two-signal system that can activate T cells in 
vitro. Upon activation T cells produce cytokines and a hallmark of T cell exhaustion is a 
decrease in the ability to produce cytokines (Wherry, 2011). We activated PBMC cultures 
from healthy controls and SSc patients by using anti-CD3 anti-CD28 coated Dynabeads® 
and determined cytokine production using ELISAs. 
 Upon in vitro stimulation SSc PBMCs produced less IFN-γ (Figure 15A) which is 
a reported sign of T cell exhaustion (Wherry, 2011). The PBMC cultures also produced 
less IL-10 and IL-17A (Figure 15B, 15C). This decrease in cytokine production upon in 
vitro stimulation suggests an overall exhaustion phenotype of SSc PBMCs that can be 
quantified by a decrease in function. This decrease in function supports the hypothesis 
that an increase in co-IR expression is not just a sign of activation, but a marker of 
exhaustion.  
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Figure 15. Decreased cytokine production of SSc PBMCs compared with HCs upon 
stimulation with anti-CD3 and anti-CD28  
PBMCs were stimulated with anti-CD3 and anti-CD28 for 24 hours and supernatant was 
collected and ELISAs were performed to detect secreted cytokines. (A) IFN-γ (ng/ml) 
produced by HC (blue symbols) and SSc (red symbols) PBMCs (B) IL-10 (pg/ml) 
produced by HC and SSc PBMCs (C) IL-17A (pg/ml) produced by HC and SSc PBMCs. 
Statistics were done with t test ** p≤ 0.001 
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4.2 NK cells in SSc show potential for dysfunction  
 NK cells in SSc have been reported to be dysfunctional showing decreased IFNγ 
production and cytotoxicity (Horikawa et al., 2005). In our SSc patient cohort NK cells 
showed increased expression of the co-IR TIM-3 which has been shown to regulate NK 
cell function (Ndhlovu et al., 2012; Sun et al., 2016; Li et al., 2017). NK cells that 
express TIM-3 produce more anti-inflammatory and less pro-inflammatory cytokines and 
are less cytotoxic (Li et al., 2017). Blocking TIM-3 increases degranulation of NK cells 
(Sun et al., 2016) and Gal-9, a ligand for TIM-3, increases the production of anti-
inflammatory cytokines NK cells produce (Li et al., 2017).  
 CD56med CD16bright NK cells are the mature cytotoxic subset of NK cells in 
circulation (Punt, Owen and Caligiuri, 2001). CD3-CD56medCD16bright NK cells were 
sorted from healthy controls and SSc patients and placed in a cytotoxicity assay with a 
target cell line. The amount of cell death of the target cell line was quantified with a live 
dead dye representing the amount of cell death induced by NK cell cytotoxicity. In 3 
healthy people and 3 patients tested we saw a trend towards decreased cytotoxicity in SSc 
patients compared to healthy controls (Figure 16A). We also saw a decrease in CD107a 
staining in SSc NK cells versus healthy control NK cells (Figure 16B) indicating the 
decrease in target cell death by SSc NK cells is due to a defect in degranulation.  
 Our data supports previous reports that NK cells in SSc patients are defective 
although the role of TIM-3 in this phenotype still needs to be elucidated.  
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Figure 16. NK cell dysfunction in SSc shown by cytotoxicity and degranulation 
 NK cells were incubated with a target cell line to measure NK cell cytotoxicity (A) % 
cell death of target cells (B) CD107a expression of NK cells by mean fluorescent 
intensity (MFI). 
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4.3 Modulation of cytokine production by co-IR blockade in SSc PBMCs  
 To directly test whether co-IRs differentially regulate T cell responses in SSc 
patients and healthy subjects, we designed an assay using monocyte-derived DCs from a 
healthy donor as an allogeneic stimulus in a mixed lymphocyte reaction (MLR). This 
assay requires cognate T cell-DC interactions for T cell activation and hence facilitates 
physiologic engagement of co-IRs on the T cells with their ligands on the DCs (Stecher et 
al., 2017). For this reason, an MLR is often used to test the functionality of novel 
checkpoint inhibitors for cancer immunotherapy (Wang et al., 2014; Stewart et al., 2015; 
Lázár-Molnár et al., 2017) By using the same DC donor to stimulate responders, differing 
amounts of inhibitory receptor ligands present on DCs were eliminated as a variable. 
Blocking antibodies for PD-1, TIGIT, and TIM-3 were added to the MLR to prevent the 
binding of ligands to the receptors. In a first set of experiments, we confirmed that 
antibody treatment did not affect the viability or ratios of the CD4+ and CD8+ T cell 
subsets in the MLR cultures (Figure 17). Next, supernatants from MLR cultures were 
collected and the presence of fourteen cytokines measured using a multiplex platform. As 
expected, the amount and types of cytokines produced by individual subjects showed 
significant variability (Figure 18). Nevertheless, two distinct profiles could be readily 
observed: subjects showing a response dominated by the pro-inflammatory cytokines 
IFN-, IL-6 and TNF (HC#1, #2, #3 and #4; SSc#1, SSc#2, SSc#3) versus subjects with 
a more diverse cytokine response and increased presence of TH2 cytokines (HC#5, 
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SSC#4, SSc#5, SSc#6). In most cases, co-IR blockade did not appear to selectively 
promote the production of specific cytokines and hence did not lead to dramatic changes 
in the composition of patient-specific cytokine profiles (Figure 18). In 4/5 healthy and 4/6 
SSc individuals, at least two of the co-IR-blocking antibodies increased the total amount 
of cytokines produced. In both healthy and SSc subjects, PD-1 appeared the strongest 
regulator of cytokine secretion (Figure 18, Figure 19). However, in SSc patients, the role 
of TIGIT and TIM-3 was modest, while in most healthy subjects TIGIT and/or TIM-3 
were potent secondary regulators of total cytokine secretion (Figure 19). Interestingly, 
there was significant patient-specific variation in cytokine-regulating activities of co-IRs.  
This experiment demonstrated that co-IR expression in SSc PBMCs is not exclusively a 
marker of a dysfunctional immune system, but that interactions of co- IRs with their 
ligands can actively regulate T cell effector functions and hence may play a role in T cell-
dependent pathogenic processes in SSc.       
To establish whether co-IR blockade during MLR cultures affected the cytokine 
response of healthy and SSc immune cells differentially, the large data set was analyzed 
using advanced bioinformatics and mathematical modeling. Unsupervised hierarchical 
clustering of cultures from subjects with various treatments and cytokines resulted in 
donors, rather than treatment groups, clustering together, masking any indication of 
potential effects of the blocking antibodies on cytokine production (Figure 20). 
Therefore, to determine whether the activities of PD-1, TIGIT and TIM-3 in SSc and 
healthy subjects could be differentiated, we performed Partial Least Squared Regression 
Discriminant Analysis (PLSDA). PLSDA is a mathematical analysis method that uses 
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latent variables (LVs) to determine which parameters contribute to causing the greatest 
difference between samples. PLSDA is useful when the behavior of multiple analytes of 
interest, in this case cytokines, are known to be interdependent and can reveal 
combinations of cytokines whose fluctuation as a group maximally correlates with the 
anti-co-IR antibody treatments (Lau et al., 2012; Bengsch et al., 2016). Samples of each 
treatment group were normalized relative to isotype-treated controls to account for the 
large differences in total cytokine produced between subjects. Then, samples were 
mapped onto three dimensional latent variable space and connected with lines that meet 
at their centroid (Figure 21A). In SSc subjects our analysis showed that cytokine 
secretion profiles differed in anti-PD-1-treated cells, compared to anti-TIM-3 and -
TIGIT, with a model confidence of 88%; this distinction was not found in samples from 
healthy controls (Figure 21B). The PLSDA model was unable to show any differences 
between anti-TIGIT or anti-TIM-3 in healthy controls and SSc subjects. Multiple 
cytokines contributed to LV1, which separated anti-PD-1 treatment from anti-TIGIT and 
-TIM-3 in SSc patients (Figure 21C). Increased overall production of IL-10, IL-13, IL-2, 
IL-21, and IL-4 in the anti-PD-1 treated SSc samples most significantly contributed to the 
distinction, as determined by VIP score. This analysis thus strengthens the conclusion 
that in SSc patients PD-1 continued to exert its normal function of actively inhibiting T 
cell cytokine production, but the TIGIT and TIM-3 pathways, while actively controlling 
cytokine secretion in healthy controls, became defective or refractory to reversal. Such a 
separation between the functionality of PD-1 on the one hand and TIGIT/TIM-3 on the 
other hand, has not been previously demonstrated in a human autoimmune disease.  
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Table 5. Clinical features of Systemic Sclerosis Patients and Healthy Controls used 
for in vitro Culture Experiments 
Characteristic    HC   SSc 
     n=5   n=6 
Sex, number males/females  1/4   1/5 
Age               53 (37-69)            62 (48-67) 
Age of Onset, median   NA             53 (33-67) 
Disease Duration    NA    9 years (2-27) 
Race, Hispanic-White/Black/White 0/0/5   0/0/6 
Number dSSc/lSSc   NA   1/5 
Modified Rodnan Skin Score  NA   4 (0-17) 
Lungs 
 ILD    NA   1 
 PAH    NA   3 
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Figure 17. Cell counts and viability in MLR cultures 
(A) Percentage of live cells in MLR culture as determined by 123 eCount beads 
(eBioscience) and flow cytometry, comparing the effects of the addition of an Isotype, 
anti-PD-1, anti-TIGIT, and anti-TIM-3 antibodies to the culture.  
(B-C) Percentage of CD4+ T cells (B) and CD8+ T cells (C) within the live cell gate in 
MLR cultures comparing the effects of the addition of Isotype, anti-PD-1, anti-TIGIT, 
and anti-TIM-3 antibodies to the culture. 
 (D-E) Total number of CD4+ T cells (D) and CD8+ T cells (E) in MLR cultures treated 
with Isotype, anti-PD-1, anti-TIGIT, and anti-TIM-3 antibodies  
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Figure 18. Co-IRs Exhibit Subject-specific Activities in Controlling Lymphocyte 
Cytokine Production 
PBMCs from SSc and healthy subjects were stimulated with DCs from a healthy donor in 
the absence or presence of anti-PD-1, anti-TIGIT or anti-TIM blocking antibodies and 
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Figure 18. Co-IRs Exhibit Subject-specific Activities in Controlling Lymphocyte 
Cytokine Production  
PBMCs from SSc and healthy subjects were stimulated with DCs from a healthy donor in 
the absence or presence of anti-PD-1, anti-TIGIT or anti-TIM blocking antibodies and 
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supernatants analyzed with a 14 cytokine multiplex assay. Bar graphs show the amount 
(pg/ml) of each of the indicated cytokines produced by individual healthy and SSc 
donors. Dotted line indicates the level of total cytokine produced in the isotype control 
cultures. 
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Figure 19. Fold Change in Cytokine Production upon in vitro co-IR Blockade 
Graphs show the fold change of total measured cytokines after co-IR blockade relative to 
isotype controls, as calculated from the data in Fig. 18. Each symbol represents an 
individual donor. Bars show the average ± SEM. 
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Figure 20.  Hierarchical Clustering of Cytokine Production.  
Heatmap of the quantification of cytokines in the supernatants from MLR cultures treated 
with blocking antibodies to co-IRs.  
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Figure 21.  Blocking PD-1, but not TIGIT and TIM-3, modulates Cytokine 
production in SSc PBMCs  
Multiplex cytokine data was subjected to PLSDA to identify variations in patterns of 
cytokine production caused by co-IR blocking antibodies, after normalization with 
isotype control values. Graphs show data points from each culture condition of SSc (A) 
and healthy (B) donors mapped onto three dimensional LV space and connected with 
lines that meet at their centroid. (C) Bar graph shows the contribution of cytokines from 
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SSc MLR cultures to LV1. Asterisks designate cytokines that contributed most to LV1 
separation in this model, as determined by VIP score.    
 
4.4 Altered T cell cytokine production after co-IR blockade modulates SSc fibroblast 
activation 
Much of the pathogenesis of SSc is driven by fibrosis in target organs. It is 
thought that pathogenic fibroblasts produce large amounts of collagen leading to loss of 
cellularity and elasticity in the skin and internal organs (Pattanaik et al., 2015). To 
explore whether blocking co-IRs on T cells could have a potential effect on this cell type, 
we cultured SSc primary fibroblasts for 24 hours with the supernatants collected from 
MLR cultures in Figure 18. Fibroblasts were washed and RNA isolated for NanoString 
analysis of genes previously described to be important for SSc disease pathogenesis (Lisa 
M Rice et al., 2015). Interestingly, hierarchical clustering revealed that the two main 
clusters are largely driven by the two distinct cytokine signatures identified in Figure 18: 
the “pro-inflammatory” group and the “diverse/Th2” group (Figure 18). Within these two 
groups, donor-specific patterns of gene expression appeared the most similar. Since our 
data in Figure 18 demonstrated that blocking co-IRs mostly resulted in quantitative, 
rather than qualitative, changes in cytokine production, it is perhaps not surprising that 
supernatants from treated cultures did not cause uniformly clustered changes in the basic 
fibroblast gene expression patterns (Figure 22). Next, we examined whether multivariate 
mathematical modeling was capable of distinguishing the effects of anti-co-IR treatment 
on fibroblast gene expression after exposure to culture supernatants. Feature selection 
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using the LASSO algorithm was performed, resulting in narrowing our gene set from 53 
to 21 genes. Subsequently, PLSDA was applied to identify patterns of gene expression 
that differentiated the treatment groups. Surprisingly, we found that fibroblasts treated 
with supernatants from anti-TIM-3-treated MLRs from both SSc patients and healthy 
controls had a distinctly modified gene expression profile from the anti-PD-1 and anti-
TIGIT treatments (Figure 23A). This distinct gene expression profile from the anti-TIM-3 
group separated based on LV1 (Figure 23B). Since TIM-3 did not strongly regulate the 
12 measured cytokines in SSc lymphocytes (Figure 21), it is likely that an unknown 
factor, induced after TIM-3 blockade, is an important regulator of SSc fibroblast gene 
expression. Importantly, the main drivers of LV1 were pro-fibrotic genes, suggesting that 
TIM-3 might play a protective role in SSc fibrosis. Contrary to TIM-3, anti-PD-1 
treatment did not appear to drive gene expression changes in fibroblasts, suggesting that 
PD-1 mostly controls the amount of cytokines produced, without significantly changing 
the composition of the supernatants.  
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Figure 22. Hierarchical Clustering of Fibroblast Gene Expression.  
 SSc fibroblasts were cultured for 24 hrs with supernatants from MLR cultures in Fig. 18. 
Fibroblast RNA was prepared and expression of selected genes measured with 
Nanostring. Heatmap shows hierarchical clustering of gene expression vs anti-PD-1-, 
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anti-TIGIT-, anti-TIM-3- and isotype-treated cultures of each individual healthy and SSc 
donor. 
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Figure 23. Blocking TIM-3 in MLR cultures promotes the production of soluble 
factors altering SSc Fibroblast Gene Expression 
SSc fibroblasts were cultured for 24 hrs with supernatants from MLR cultures in Fig. 18. 
Fibroblast RNA was prepared and expression of selected genes measured with 
Nanostring. (A) PLSDA was applied to Nanostring data and plot shows LV1 for gene 
expression data of fibroblasts exposed to supernatants from each anti-co-IR antibody-
treated MLR. Data points represent values for each individual healthy and SSc donor. (B) 
Bar graph shows the contribution of individual genes to LV1. Asterisks designate genes 
that contributed most to LV1 separation of anti-TIM-3-mediated changes, as calculated 
by VIP score. 
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Figure 23. Blocking TIM-3 in LR cultures promotes the production of soluble 
factors altering SSc Fibroblast Gene Expression   
SSc fibroblasts were cultured for 24 hrs with supernatants from MLR cultures in Fig. 18. 
Fibroblast RNA was prepared and expression of selected genes measured with 
Nanostring. (A) PLSDA was applied to Nanostring data and plot shows LV1 for gene 
expression data of fibroblasts exposed to supernatants from each anti-co-IR antibody-
treated MLR. Data points represent values for each individual healthy and SSc donor. (B) 
Bar graph shows the contribution of individual genes to LV1. Asterisks designate genes 
that contributed most to LV1 separation of anti-TIM-3-mediated changes, as calculated 
by VIP score. 
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4.5 Co-IR-dependent modulation of cytokine production in SSc T cells responding to 
autologous DCs 
 Allograft reactions depend on the presentation of major and minor-
histocompatability mismatched antigens to promote activation (Jaffee and Claman, 
1983). While this provides a strong stimulus as well as consistent expression of co-IR 
ligands from reaction to reaction, the recognition of these mismatched peptides is 
variable from person to person. In order to try a modified approach, we used dendritic 
cells derived from monocytes from the same donor as the PBMCs. To know which cells 
were responsible for cytokine secretion, we performed intracellular cytokine (IC) staining 
as our read-out of changes in cytokine production in autologous monocyte-derived 
dendritic cell reactions. 
 PBMCs were isolated from patients using density centrifugation separation. After 
isolation, a subset of cells was frozen as described in the methods and from the other half 
we isolated CD14+ monocytes which were differentiated into monocyte-derived dendritic 
cells. These monocyte-derived dendritic cells provided the stimulus, along with an anti-
CD3 antibody, for the thawed PBMCs from the same patient to provide for an autologous 
reaction. Within the culture we added blocking antibodies to PD-1, TIGIT, or TIM-3. To 
look at their role in modulating cytokine production on an individual cellular level, cells 
were stained for flow cytometric analysis.  
 No obvious differences in the production of intracellular cytokines were observed 
between patients and healthy controls. However, CD8+ T cells trended towards a 
decrease in IFN-γ production in SSc patients, supporting the notion of an exhaustion 
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phenotype (Figure 24). Upon the blockade of the co-IRs PD-1, TIGIT, and TIM-3, using 
monoclonal antibodies, we also observed no significant changes in cytokine production 
when looking at individual cytokines produced by individual cell types. In order to 
determine the overall role of co-IR blockade on the overall cytokine production across 
multiple cell types we utilized the multi-dimensional PLSDA analysis (Figure 25). Data 
of Tconv, Tregs, and CD8+ cells producing IL-10, IFN-γ, IL-2, and IL-13 were used to 
generate the mathematical model. 
 Once again the anti-PD-1 separated from anti-TIGIT and anti-TIM-3 in multi-
dimensional space. This separation of anti-PD-1 from anti-TIGIT and anti-TIM-3 was 
driven by a difference along Latent Variable 1 (LV1) while the separation of donors was 
separated upon Latent Variable 2 (LV2). This separation further supports the notion that 
PD-1 is a stronger regulator of cytokine production. Unlike the blockade of co-IRs in an 
MLR, however, this separation of anti-PD-1 from anti-TIGIT and anti-TIM-3 was seen in 
both SSc patients and healthy controls.  
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Figure 24. IFN-γ Production by CD8+ T cells in SSc shown by intracellular cytokine 
staining. 
PBMCs were stimulated with autologous DCs and anti-CD3, collected, and stained for 
flow cytometric analysis. Graph shows intracellular cytokine production of IFN-γ by 
CD8+ T cells 24 hours after autologous DC stimulation. 
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Figure 25. PLSDA of Intracellular Cytokine production shows the Blockade of PD-1 
Modulates Cytokine Production. 
SSc and healthy donors mapped onto three dimensional LV space and connected with 
lines that meet at their centroid with anti-PD-1 treated cells in red, anti-TIGIT treated 
cells in teal, and anti-TIM-3 treated cells in blue. 
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DISCUSSION 
 Co-IRs play critical functional roles in in vivo models of autoimmune 
disorders (Anderson, Joller and Kuchroo, 2016) and in chronic viral infections and cancer 
(Wherry, 2011). In HIV and cancer, increased expression of PD-1 and the co-expression 
of multiple inhibitory receptors is linked with a corresponding decrease in effector 
function of T cells (Wherry, 2011), a state described as “T cell exhaustion.” Blocking co-
IRs can restore effector function, as has been shown in successful immunotherapy for 
cancer (Yang, 2015). However, epigenetic mechanisms dictating exhaustion, such as 
methylation, can provide a barrier to lymphocyte rejuvenation (Ghoneim et al., 2017). 
Our findings that anti-TIGIT and anti-TIM-3 were largely ineffective in enhancing 
cytokine production in PBMCs from SSc patients suggest that a more robust state of T 
cell exhaustion, perhaps epigenetically controlled, is present in SSc patients compared to 
healthy controls. Interestingly, cytokine responses in individual subjects were not always 
controlled by the same co-IRs, a finding with potential repercussions for therapeutic use 
of these checkpoint inhibitors. Our antibody-blocking experiments revealed that PD-1 
played the dominant role in modulating cytokine secretion. PD-1 has extensively been 
characterized as limiting the production of cytokines and other functions of immune cells. 
It is therefore feasible that increased PD-1 expression in SSc represents a regulatory 
mechanism attempting to limit tissue damage. However, absence of the ligands engaging 
PD-1 in the tissue microenvironment may preclude successful engagement of this 
pathway.  Alternatively, engagement of PD-1, TIM-3 or TIGIT may suppress some T cell 
cytokines but not others, leading to subtle skewing of cytokine profiles. Such changes in 
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cytokine signatures due to aberrant expression of co-IR combinations and, perhaps, their 
ligands in fibrotic tissues may impinge on disease processes. In support of this 
hypothesis, our data show that co-IR blockade during an in vitro immune response 
provokes changes in the composition of soluble factors present in culture supernatants 
that can have an impact on fibroblast gene expression. In some cases, these changes may 
be caused by the cytokines we measured and that have known activities in fibroblasts. IL-
13 for example is a potent inducer of collagen production (Chiaramonte et al., 1999). One 
intriguing possibility however, revealed by mathematical modeling, was that TIM-3 
modulated the production of as yet unidentified soluble factors in the MLR that had a 
distinct effect on SSc fibroblast gene expression more so than the cytokines we measured. 
One obvious candidate to initiate these changes would be the pro-fibrotic cytokine TGF-
β, but recombinant TGF-β alone was not able to recapitulate the gene expression profile 
induced by any of the co-IR blocking antibodies (data not shown).  
 In summary, functional analysis and mathematical modeling of the impact of 
these co-IRs on disease-relevant cytokine production and fibroblast gene expression, 
suggests that these pathways play a role in SSc pathophysiology and may be amenable 
targets for therapy.  
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CHAPTER FIVE: CO-INHIBITORY RECEPTORS IN AN IN VIVO MODEL OF 
SSC 
  
Rationale 
 While we observed an increase in co-IRs in the blood of SSc patients, in order to 
begin to elucidate their potential importance in disease pathogenesis we used an in vivo 
system. SclGvHD is an MHC matched minor-histocompatability mismatched graft-
versus-host reaction that recapitulates many aspects of SSc. This animal model allows for 
the manipulation of co-IRs in vivo to understand the role of these receptors in disease 
pathogenesis.  
 Many aspects of this in vivo model have been studied to show the model’s 
relevance to SSc. Fibrosis, vascular damage, and autoantibody production have all been 
reported in this model (Ruzek et al., 2004). The gene expression signature of fibrotic skin 
in these mice is similar to the described inflammatory subset of SSc patients showing a 
tissue-relevant phenotype (Greenblatt et al., 2012). The immune system plays an 
important role in sclGvHD. The phenotype is dependent on CD4+ T cells (Hamilton, 
1987), although not the memory subset (Anderson, McNiff and Yan, 2003). STAT3 
signaling in CD4+ T cells is an important contributor to the disease supporting an 
important role of cytokines, likely IL-6, in promoting fibrosis in this system (Radojcic et 
al., 2010). The IL-13/IL-4 receptor complex specifically plays a role in disease 
pathogenesis (Greenblatt et al., 2012) again showing an important link to human SSc 
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which is thought to be at least partially driven by the TH2 type immune response 
(O’Reilly, Hügle and van Laar, 2012). 
 Co-IRs have only begun to be explored in this in vivo system. The role of PD-1 in 
sclGvHD is the first co-IR to be documented. Like in human SSc PD-1 is upregulated on 
CD4+ T cells in sclGvHD (Fujiwara et al., 2014). PD-1 knockout donor cells produce a 
more lethal sclGvHD phenotype indicating a protective role of PD-1 in this system. The 
blockade of PD-1 with blocking antibodies in vivo and a lack of PD-1’s ligand PDL-1 in 
host tissues also increases disease severity (Fujiwara et al., 2014). This strong in vivo 
phenotype suggests an important role of PD-1 in sclGvHD and potentially human SSc. 
 While PD-1 has been explored in sclGvHD other co-IRs have not. The 
observation that TIGIT and TIM-3 are also upregulated in SSc PBMCs provides an 
important direction for potential in vivo manipulation of these receptors. 
 
RESULTS 
5.1 SclGvHD T cells show an increase in co-IR expression 
 As previously reported, Balb/c Rag-/- mice transplanted with B10.D2 splenocytes 
lost weight and showed a GvHD phenotype. However, not all mice became externally ill. 
From experiment to experiment the penetrance deviated from 10%-80%. Although often 
mice did not present with fur loss, we could still see histological changes in their skin 
(Figure 26). Balb/c Rag-/- mice that received B10.D2 splenocytes had a loss of 
subcutaneous fat and an increase in dermal thickness with a larger more irregular 
epidermal layer. Despite sclGvHD mice consistently showing some pathological changes 
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compared to syngeneic controls, the variability of the phenotype poses a problem in 
quantifying any potential changes in disease phenotype with treatment. 
 While sclGvHD has been reported to be a good model of human SSc in many 
regards, we were interested to see if the novel phenotype of increased co-IRs we 
observed in SSc PBMCs would be mimicked in an animal model. Increases in PD-1 on 
CD4+ T cells had been previously reported (Fujiwara et al., 2014) which matched a 
similar phenotype seen in SSc PBMCs. We also observed increases in PD-1 expression 
on CD4+ T cells from sclGvHD mice compared to syngeneic controls. Tconv T cells in 
the blood, defined as CD4+ T cells that lacked FoxP3 expression, had a statistically 
significant increase in PD-1 expression in the GvHD mice, while PD-1 on Tregs, FoxP3+ 
CD4+ cells, only trended towards an increase in expression (Figure 27A-B). While 
human SSc CD8+ cells only trended towards an increase in PD-1 expression, PD-1 
expression on circulating CD8+ cells in the mice was strongly increased compared to the 
circulating CD8+ cells in the control animals (Figure 27C). Our data also indicates that 
TIM-3 is strongly induced on T cells, although a low sample size of mice that received a 
syngeneic transplant does not allow for statistical testing (data not shown). 
 TIM-3 is highly expressed on CD4+ T cells in the blood of sclGvHD mice. Mice 
with lower grade disease have higher levels of TIM-3 than those with higher grade 
disease (Figure 28A and B), raising the possibility that TIM-3 plays a protective role in 
disease pathogenesis. TIM-3+ Tregs have been shown to be more suppressive than TIM-
3 negative Tregs (Gautron et al., 2014) suggesting the increase in TIM-3 on sclGvHD 
Tregs in circulation could be blunting an immune response, decreasing the disease score. 
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Conversely PD-1 is expressed at higher levels on Tconv cells from mice with a higher 
disease score (Figure 28C-D) suggesting unique functions for different co-IRs in 
sclGvHD. 
 
 
Figure 26. Histology of Skin of Control and sclGvHD mice shows increased dermal 
thickness in sclGvHD mice 
(A) H&E stain of the skin of a control mouse. (B) H&E stain of the skin of a mouse with 
sclGvHD.   
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Figure 27. Increased expression of PD-1 on T cells from sclGvHD mice compared to 
Control Mice 
Balbc Rag-/- mice were injected with splenocytes from wild type Balb/c or B10.D2 mice. 
After 3-4 weeks splenocytes from the transplanted mice were collected and stained for T 
cell subsets and co-IRs. Percent of Tconv cells (A), Tregs (B) and CD8+ T cells (C) that 
are PD-1+ from the blood of control and sclGvHD mice. Statistics was done with t test * 
p≤ 0.05 
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Figure 28. Co-IR Expression is changed on CD4+ T cells from higher Grade 
sclGvHD mice. 
Balb/c Rag-/- mice were injected with splenocytes from wild type Balb/c or B10.D2 
mice. After 3-4 weeks splenocytes from the transplanted mice were collected and stained 
for T cell subsets and co-IRs. (A) Percent of Tconv cells from the blood that express 
TIM-3 from mice with a low disease grade of 0-2, a medium grade of 3-4, and a high 
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grade of 5-6. (B) Percent of Tregs from the blood that express TIM-3 from mice with a 
low disease grade of 0-2, a medium grade of 3-4, and a high grade of 5-6. Statistics was 
done with t test * p≤ 0.05, * p≤ 0.001, and *** p≤ 0.0001. (C) Percent of Tconv cells 
from the blood that express PD-1 from mice with a low grade of 0-2, a medium grade of 
3-4, and a high grade of 5-6. (D) Percent of Tregs from the blood that express PD-1 from 
mice with a low disease grade of 0-2, a medium grade of 3-4, and a high grade of 5-6. 
Statistics was done with t test * p≤ 0.05, * p≤ 0.001, and *** p≤ 0.0001. 
 
 
5.2 Anti-TIM-3 Treatment of sclGvHD  
 Modulating the co-IR TIM-3 in vivo affects some disease states. Blocking TIM-3 
in EAE exacerbates the clinical disease score (Monney 2002), while blocking it in 
conjunction with blocking PD-1 increases virus specific CD8+ T cell responses in 
chronic LCMV (Jin et al., 2010). It has already been reported that blocking PD-1 is 
detrimental to sclGvHD mice in vivo (Fujiwara et al., 2014). In order to determine the 
role of other co-IRs we found to be aberrantly expressed in human SSc we treated 
sclGvHD mice with blocking antibodies to the co-IR TIM-3. The blockade of TIM-3 in 
vivo did not have any effect on the severity of disease based on grade of external disease 
or weight loss (Figure 29).  
 In order to determine if the blockade of TIM-3 in vivo had any effect on the 
effector function of immune cells in sclGvHD, we isolated splenocytes from mice and 
stimulated them in vitro with PMA & Ionomycin. We found no differences in the 
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production of cytokines by T cells in the spleens of sclGvHD mice treated with anti-TIM-
3 compared with those treated with an isotype control (Figure 30). 
 While blocking TIM-3 in sclGvHD had no effect on the state of the disease or on 
the effector function of T cells ex vivo, this finding is not without precedent. TIM-3 
blockade alone also has a minimal effect on virus specific CD8+ T cells in LCMV-
infected mice. Although like in sclGvHD there is an increase in TIM-3 expression in 
chronic LCMV compared to a healthy mouse, a blockade of PD-1 along with TIM-3 was 
more effective at enhancing virus-specific CD8+ T cells than TIM-3 alone (Jin et al., 
2010).  
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Figure 29. Disease Severity of sclGvHD mice treated with anti-TIM-3 
Graphs A, B and C show disease grades of three separate experiments in which sclGVHD 
mice were treated with an Isotype control antibody (A: n=6, B: n=7 and C: n=4) versus a 
blocking antibody to TIM-3 (A: n=6, B: n=7 and C: n=4).  
 112 
 
 
 
Figure 30. Cytokine production of T cells from mice with sclGvHD treated with 
anti-TIM-3 
Splenocytes from sclGvHD mice were isolated and stimulated in culture with PMA and 
ionomycin and collected and stained for flow cytometric analysis. (A) Intracellular 
cytokine production of Tconv cells. (B) Intracellular cytokine production of Tregs. (C) 
Intracellular cytokine production of CD8+ T cells 
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5.3 Anti-TIGIT Treatment of SclGvHD 
 The blockade of TIGIT has been shown to modulate autoimmune phenotypes. In 
a collagen-induced arthritis (CIA) model of arthritis, blocking TIGIT accelerated disease 
onset (Levin et al., 2011), and in the EAE model of MS, TIGIT-/- mice developed worse 
disease (Joller et al., 2011). However, upon the treatment of sclGvHD mice with 
blocking antibodies to TIGIT no difference in disease severity was observed when 
compared with those treated with an isotype control (Figure 31).  
 Similar to anti-TIM-3 treatment, the blockade of TIGIT in vivo did not affect the 
cytokine production of lymphocytes when stimulated in vitro following treatment (Figure 
32). Like TIM-3 in vivo blockade of TIGIT has been shown to work in concert with the 
blockade of PD-1 to eradicate tumors in mice (Johnston et al., 2014). The inability of 
TIGIT alone to re-establish an effective immune response in tumors mimics the inability 
of the blockade of TIGIT alone to modulate an autoimmune phenotype. 
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Figure 31. Disease Severity of sclGvHD mice treated with anti-TIGIT 
Graphs A and B show disease grades of two separate experiments in which sclGVHD 
mice were treated with an isotype control antibody (A: n=4, B: n=6) versus a blocking 
antibody to TIGIT(A: n=4, B: n=7))  
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Figure 32. Cytokine production of T cells from mice with sclGvHD treated with 
anti-TIGIT 
Splenocytes from sclGvHD mice were isolated and stimulated in culture with PMA and 
ionomycin and collected and stained for flow cytometric analysis. (A) Intracellular 
cytokine production of Tconv cells. (B) Intracelluar cytokine production of Tregs. (C) 
Intracelluar cytokine production of CD8+ T cells 
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DISCUSSION 
 Although co-IRs have similar downstream roles, they possess context-specific 
functions. CTLA-4 (Tivol et al., 1995) and PD-1 (Nishimura et al., 1999) knockout mice 
develop spontaneous autoimmunity, but TIGIT (Levin et al., 2011), TIM-3 (Sánchez-
Fueyo et al., 2003), and LAG-3 (Workman and Vignali, 2005) mice do not, although 
mice lacking these co-IRs do have a predisposition to autoimmunity. The blockade of 
PD-1 in vivo is a potent promoter of immune responses: from anti-tumor responses 
(Baumeister et al., 2016) to reestablishment of viral responses (LMCV) to promoting 
autoimmunity (Wherry, 2011). TIGIT and TIM-3 have their own clinical implications in 
cancer, chronic viral infections, autoimmunity, but their blockade produces a less potent 
promotion of active immune responses (Anderson, Joller and Kuchroo, 2016). 
 The idea that PD-1 is better at reversing stalled immune responses is supported by 
both in vitro and in vivo work. In vitro, PD-1 blockade has a stronger effect on changing 
cytokine production compared with the blockade of TIGIT and TIM-3 in SSc patients. 
This is mimicked in mice with sclGvHD mice treated with anti-PD-1 having increased 
disease (Fujiwara et al., 2014) while blocking antibodies to TIGIT or TIM-3 had no 
effect.  
 However, a caveat to our animal work is the variability of our model. The range 
of disease severity from animal to animal and experiment to experiment makes drawing 
any broad conclusions difficult. For example, anti-TIM-3 treatment did not change the 
average disease severity over 3 separate experiments. However, in the first experiment 
the anti-TIM-3-treated mice did better than those treated with an isotype control, while 
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the second and third time there was virtually no difference between treatment groups. 
This is further complicated by the fact the average disease score was higher in the first 
experiment than the second and third. The question thus arises: if blocking TIM-3 
ameliorates the disease, is the disease severity predisposed to be greater? 
 This potential for TIM-3 to ameliorate a scleroderma-like phenotype is unlikely 
due to the response to the blockade of TIM-3 in the bleomycin lung model of SSc-ILD. 
Mice treated with the chemical bleomycin develop fibrosis and so this model is often 
used to mimic SSc (Beyer et al., 2010). Blocking TIM-3 in a bleomycin model of 
pulmonary fibrosis exacerbates the disease, suggesting a protective role for TIM-3 in SSc 
(Isshiki et al., 2017). 
 The inability of TIGIT to modulate sclGvHD is surprising due to TIGIT’s role in 
controlling TH2 immune responses. The blockade of TIGIT in allergic airway disease 
decreases disease severity linking its function to the ability to control TH2 responses 
(Kourepini et al., 2016). TIGIT-positive Tregs also selectively inhibit TH1 and TH17 
responses, but are unable to control TH2 (Joller et al., 2014). Tregs in human SSc have 
increased TIGIT expression which may exacerbate a TH2 driven disease phenotype. 
TIGIT has the potential to modulate in vivo TH2 responses so it is interesting that 
blocking TIGIT in sclGvHD does not modify the phenotype. This raises the question 
whether the inability to see any changes in sclGvHD upon TIGIT blockade is due to the 
variability of the model or to the inability of TIGIT blockade alone to have a strong 
enough effect on immune cell function in vivo in this model.  
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CHAPTER SIX: DISCUSSION 
Parts of this chapter were originally published in: Fleury, M. Belkina, A. Proctor, 
E. Zammitti, C. Simms, R. Lauffenburger, D. Snyder-Cappione, J. Lafyatis, R. Dooms, 
H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors 
PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis, 
Arthritis & Rheumatology.  https://doi.org/10.1002/art.40399 
 
6.1 Summary of Results 
 In this study, we analyzed the expression and function of the co-IRs PD-1, TIM-3, 
TIGIT and LAG-3 in SSc PBMCs. PD-1 and TIGIT are increased and co-expressed on 
multiple T cell subsets from SSc patients while TIM-3 is increased on the cytotoxic 
CD16+CD56med subset of NK cells. Co-IRs play distinct roles in regulating the 
production of cytokines and their functionality differed significantly between individual 
donors. Our data has also shown a decrease in lymphocyte function, which could be 
linked to the observations of increased co-IR expression. Importantly, TIGIT and TIM-3, 
but not PD-1, showed reduced activity in SSc patients vs. healthy controls. Our 
observations thus support a cell-specific altered expression pattern of co-IRs in SSc 
immune cells, rather than a broad upregulation of these receptors. Moreover, co-IRs play 
complex and patient-specific roles in regulating cytokine production, a finding with 
potential implications for better understanding this heterogeneous disease.      
 119 
 
 Our work has also further supported the use of the sclGvHD mouse model for the 
study of systemic sclerosis. Fujiwara and colleagues have previously shown the 
importance of PD-1 in this animal model (Fujiwara et al., 2014) and our group has 
expanded on the role of co-IRs in sclGvHD with the observation of increased TIM-3 on 
the CD4+ T cells on mice with less severe disease. While it has been published that the 
blockade of PD-1 exacerbates the disease (Fujiwara et al., 2014), we were not able to 
show any robust modulation of the disease phenotype by blocking either TIGIT or TIM-3 
in vivo.  
 
6.2 Importance for the Understanding of Immune Defects in Systemic Sclerosis 
SSc is a poorly understood autoimmune disorder that produces an extreme 
reduction in quality of life and currently has a ten year fifty percent survival rate (Elhai et 
al., 2012). Patients have few treatment options, therefore, a greater understanding of the 
underlying immunological mechanisms of the disease is needed to assess the feasibility 
of developing immunotherapies. While many studies have focused on understanding 
aberrant fibroblast differentiation in SSc, there is also evidence that immune cells and the 
cytokines they produce play a critical role in fibrosis. In many fibrotic diseases, it is well-
established that TH2 type immune responses, producing IL-4 and IL-13, promote fibrosis 
(Wynn, 2015). T-cell-derived TGF- may contribute as well (Roberts et al., 1986). In 
SSc however, robust evidence for a critical role of bona fide TH2 cells remains limited 
(O’Reilly, Hügle and van Laar, 2012). CD8+ T cells may also be a source of IL-13, as 
was demonstrated by Fuschiotti et al. in SSc peripheral blood (Fuschiotti, Medsger and 
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Morel, 2009) and skin (Fuschiotti et al., 2013). One intriguing study demonstrated that 
skin Tregs can produce IL-4 and IL-13, possibly contributing to a fibrotic phenotype 
(Macdonald et al., 2015). This finding, combined with studies indicating that bona fide 
Foxp3+ Tregs numbers are reduced in the skin of SSc patients (Antiga et al., 2010; Klein 
et al., 2011) suggests Treg deficiencies play a role in SSc. It would be of interest to 
determine whether our observation that CD45RO+ effector/memory Tregs are 
specifically reduced in SSc blood correlates with the reported decrease in tissue-resident 
Tregs. A number of recent studies indicate that TH17 cells are present in SSc and may 
contribute to the disease process (Radstake et al., 2009; Fenoglio et al., 2011). Together, 
these studies underscore the need for a better understanding of the regulatory mechanisms 
underlying the potential pro-fibrotic and pro-inflammatory functions of various T cell 
subsets in SSc.  
Co-IRs such as PD-1, TIM-3, LAG-3 and TIGIT are an important class of 
molecules controlling T cell effector responses. Our finding that these receptors are 
aberrantly expressed in SSc patients is in line with the general trend for these receptors to 
be increased in other rheumatic diseases. However, the co-IR expression patterns on 
various lymphocyte subsets show considerable disease-dependent variation. For example, 
PD-1 is increased in CD4+ and CD8+ T and NK cells from lupus patients (Bertsias et al., 
2009; Jiao et al., 2014), even though we were only able to observe a statistically 
significant increase in PD-1 on Tregs in our small SLE cohort. This increase in PD-1 is 
also seen on CD3+ T cells from psoriatic arthritis patients (Peled et al., 2015). While in 
SSc, it is only significantly enhanced in Tregs and  T cells (Figure 8). In addition, 
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serum levels of soluble forms of PD-1 and its ligand PD-L2 were recently shown to be 
elevated in SSc (Fukasawa et al., 2017). Li et al. describe increased TIM-3 on CD4+ and 
CD8+ T cells in peripheral blood from rheumatoid arthritis patients (S. Li et al., 2014). 
Our data shows no changes in TIM-3 in SSc T cell subsets, but an increase in NK cells 
(Figure 8). In lupus, TIGIT is upregulated on CD4+ T cells, but reduced in CD8+ T cells, 
NK cells and Tregs (Mao et al., 2017), an expression pattern that also does not match 
with SSc (Figure 8). Deciphering the origin and functional consequences of these 
differences constitutes an important future research direction. 
While observations of changes in co-IR expression on circulating lymphocytes in 
SSc provide suggest a role in disease pathogenesis, whether or not these changes have 
direct effects on target tissues still needs to be elucidated. We would hypothesize that 
dysfunctional lymphocytes found in circulation would migrate to SSc target tissues, such 
as the skin or lungs, and effect the tissue micro-environment. TIGIT often marks TH2 
cells (Kourepini et al., 2016) and increased TIGIT expression could reflect more cells 
producing TH2 cytokines, such as IL-13, which could skew tissue macrophages towards 
an M2 phenotype, while simultaneously promoting collagen production by fibroblasts. 
NK with increased TIM-3 are less functional (Ndhlovu et al., 2012) and if these NK cells 
migrated to tissues they could have decreased ability to clear collagen-producing 
fibroblasts. We also observed increased percentages of PD-1 TIGIT double positive 
Tregs, which could have decreased function. In target tissues these cells may be unable to 
control inflammation, further driving disease pathogenesis (Figure 33). 
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Figure 33. Increased expression of co-IRs on lymphocytes in SSc leads to increased 
pathogenesis by modulating lymphocyte function in target tissues.  
We observed increased co-IR expression on circulating lymphocytes in the blood of SSc 
patients. We hypothesize that upon entry of these cells into target tissues increased co-IR 
expression will cause changes in lymphocyte function that will perpetuate a disease 
phenotype. TIGIT has been shown to be expressed on TH2 cells and the production of 
TH2 cytokines such as IL-13 by Tconv cells could affect the tissue microenvironment by 
increasing collagen production by fibroblasts as well as promoting a M2 like phenotype 
of tissue resident macrophages. The co-expression of PD-1 and TIGIT on Tregs could 
mark less functional Tregs which could lead to an inability to control inflammation in the 
tissue microenvironment. The expression of TIM-3 on NK cells has been shown to 
decrease their function. After migration to the tissues, increased TIM-3 on NK cells in 
SSc patients may impede these cells to properly clear pathogenic activated fibroblasts 
that were contributing to the pathogenesis of the disease. 
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6.3 sclGvHD as a Model of Systemic Sclerosis 
The modulation of co-IRs in mouse models of autoimmune diseases has been well 
documented to have a potent effect on disease phenotypes (Ansari et al., 2003; Anderson, 
Joller and Kuchroo, 2016). Co-IRs typically have been described to play a protective role 
in preventing autoimmunity, with the loss of co-IRs exacerbating mouse models of T1D 
(Okazaki et al., 2011), MS (Lee and Goverman, 2013), and others. The blockade of these 
receptors with blocking antibodies have similar effects (Monney et al., 2002; Levin et al., 
2011) showing the in vivo modulation with therapeutics can have a profound effect on 
immune dysregulation in mice. 
Our group and others (Fujiwara et al., 2014) have shown that the expression of 
co-IRs is upregulated in sclGvHD, which mimics our finding that SSc patients have 
increased expression of co-IRs. While our findings in mice show that increased 
expression of TIM-3 correlates with decreased severity of sclGvHD, we found no 
correlation with disease severity in SSc patients with co-IR expression. However, very 
few of the patients in this study had a high mRSS, a clinical parameter of disease 
severity, so further study is needed to see if high skin score correlates with changes in co-
IR expression.  
In vitro, the blockade of PD-1 had a substantial effect on cytokine production 
compared to the blockade of TIGIT and TIM-3 which supports in vivo animal data that 
the blockade of PD-1 in vivo can modulate sclGvHD (Fujiwara et al., 2014), yet our data 
blocking TIGIT and TIM-3 had no substantial effect. However, we showed that blocking 
antibodies to TIM-3 in vitro had a role in changing the production of soluble factors that 
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modulated gene expression of fibroblasts, suggesting there could be a role for TIM-3 in 
SSc. Whether the lack of substantial changes in sclGvHD disease severity after anti-TIM-
3 treatment is due to the heterogeneity of the model or the inability of anti-TIM-3 to 
control immune responses in sclGvHD, there is a need for further exploration.  
 
6.4 Future Directions 
In this study we were able to show changes in co-IR expression in SSc patients in 
a cell-type specific manner and that these receptors can be modulated in vitro to change 
immune responses. These data are an important first step in showing the significance of 
co-IRs in SSc.  
In the future, gaining more knowledge of how the expression of these receptors 
correlates with disease would give us a window into the understanding of whether these 
receptors are more protective of aberrant immune responses or if they cause immune 
dysfunction that is more harmful to patients. Our patient cohort was relatively healthy 
with the majority of patients having a low mRSS and while a few patients presented with 
lung involvement, few reported FVC or other parameters of lung dysfunction that would 
allow for correlations with co-IR expression to be identified. Our mouse data with TIM-3 
expression being increased on mice with less severe disease suggests that a more diverse 
cohort of patients could lead to compelling findings of co-IRs functioning as potential 
biomarkers of disease. 
We also document a level of increased immune exhaustion in SSc patients 
compared to HCs. The decreases in effector function of T cells and NK cells in SSc as 
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well as increased co-IR expression suggests an exhausted phenotype of immune cells in 
circulating lymphocytes in SSc. The ability of PD-1 to have a greater effect on the 
modulation of cytokine production in SSc PBMCs than TIGIT and TIM-3, a finding not 
seen in HCs, also leads to a conclusion that SSc PBMCs could be at an increased level of 
exhaustion that can still be reversed by a stronger co-IR like PD-1, but not TIGIT or 
TIM-3, which have been shown in vivo to have less of a pronounced effect on immune 
function (Anderson, Joller and Kuchroo, 2016; Baumeister et al., 2016). However, co-IRs 
are increased upon activation (Triebel et al., 1990; Ishida et al., 1992), and while we see 
a cell-specific increase in co-IRs and not a broad upregulation, more work needs to be 
done to tease apart exhaustion from activation. Sorting of co-IR-positive lymphocytes 
will allow for a more specific characterization of these cells to look at exhaustion versus 
activation. The increase in PD-1 TIGIT double positive Tconv and Tregs in SSc PBMCs 
gives us an attractive subset to study. We would hypothesize that these cells are truly 
exhausted due to the expression of multiple co-IRs that often indicate a state of 
exhaustion (Wherry, 2011). 
While much of the field of T cell exhaustion has focused on CD8+ T cells 
(Wherry, 2011; Singer et al., 2016) our data of an increase in PD-1 TIGIT double 
positive CD4+ cells would suggest that CD4+ cells in SSc have a high level of 
exhaustion. The identification of a potentially unexplored exhausted CD4+TIGIT+PD-1+ 
cell subset is an exciting opportunity to add to the understanding of T cell exhaustion and 
its role in modulating aberrant immune responses. 
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Not only have CD8+ T cells dominated the field of exhaustion and the role co-IRs 
play in this dysfunctional phenotype, but T cells in general have been studied to a much 
greater extent than other cell types that express co-IRs. NK cells express the highest 
levels of TIM-3, and TIM-3 has been shown to be protective in pregnancy with pregnant 
women having higher levels of TIM-3 on circulating NK cells. Pregnant women prone to 
miscarriage possess lower levels than their pregnant counterparts who carried to term (Li 
et al., 2017). SSc patients have higher levels of TIM-3 on cytotoxic NK cells and NK 
cells are reported to be dysfunctional in SSc (Almeida et al., 2015).  
NK cells could play an important role in SSc pathogenesis. NK cells produce 
large amounts of IFN-γ (Cooper, 2001) and IFN-γ is a known repressor of fibrosis (Elias 
et al., 1990). NK cells have also been shown to be important for the clearance of fibrotic 
cells in liver fibrosis (Fasbender et al., 2016). Work still needs to be done to understand 
whether TIM-3 is responsible for decreased NK cell function in SSc, but studying the 
link between TIM-3 expression and NK cell dysfunction in SSc could play an important 
role in understanding disease pathogenesis. 
Increases in co-IR expression are often linked to chronic levels of inflammation 
(Jones et al., 2008) and SSc is known to have an increase in pro-inflammatory mediators 
in circulation including IL-6 and TNFα (Pattanaik et al., 2015). Whether increased co-IR 
expression is directly linked to disease pathogenesis or if it is just a marker of 
inflammation, is an open question that still needs to be addressed. 
Tissue-resident functions of immune cells in SSc and how co-IRs play a role are 
also interesting directions to pursue. Co-IRs use their ligands in order to affect the 
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function of immune cells (Anderson, Joller and Kuchroo, 2016). Exploring the interplay 
of infiltrating immune cells with cells that reside in target tissues and whether the 
expression of co-IR ligands by fibroblasts or other cells in tissue help modulate disease 
pathogenesis is another interesting avenue to explore. In the field of cancer 
immunotherapy, the expression of PDL-1 in the tissue is a predictor of whether or not 
PD-1 blocking antibodies are able to promote an active immune response (Zou, Wolchok 
and Chen, 2016). We would hypothesize that expression of co-IR ligands in SSc target 
tissues would be needed to regulate a pathogenic immune response in SSc. 
SclGvHD has been shown to be a representative, albeit inconsistent, model of 
SSc. The observation of increases in PD-1 and TIM-3 in sclGvHD, similar to increases 
seen in SSc, leads us to question any potential changes in TIGIT and LAG-3 in the blood 
of sclGvHD mice. Staining for TIGIT in conjunction with PD-1 would also give us 
information about increases in PD-1 TIGIT double positive CD4+ T cells in the blood of 
sclGvHD mice that could mimic human disease. Accessibility of skin from these mice 
gives us a target organ to see if changes in co-IR expression have any impact on skin 
disease which is a better indicator of whether co-IR expression and immune dysfunction 
has any direct role in disease pathogenesis. 
Our finding, that blocking TIGIT and TIM-3 in vivo does not reliably have any 
effect on sclGvHD disease pathogenesis, is interesting given the blockade of TIGIT and 
TIM-3 have less of a role in modulating cytokine production in vitro than the blockade of 
PD-1. This finding is especially interesting since blocking PD-1 in sclGvHD has been 
published to make sclGvHD worse (Fujiwara et al., 2014). This could suggest that PD-1 
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is playing a protective role in vivo and a PD-1 agonist could have some therapeutic 
effect. However, a better understanding of whether some mice respond to anti-TIGIT and 
anti-TIM-3 or if there is truly no effect will require more mice and a more comprehensive 
study of the treatment of sclGvHD mice. 
The use of other models of SSc could also provide insight into the role of co-IRs 
in vivo. Bleomycin treatment produces skin and lung fibrosis and is often used as a model 
of SSc (Beyer et al., 2010). TIM-3 has been shown to protect against pulmonary fibrosis 
in this model (Isshiki et al., 2017), although its role was due to TIM-3 expression on 
alveolar macrophages which is not a cell type we have explored. Fibrosis induced by 
bleomycin treatment is more consistent than sclGvHD (Beyer et al., 2010) and could give 
clearer answers to the role of co-IRs in immune regulation of in vivo fibrosis. 
While co-IRs have been shown to be important in controlling autoimmune 
phenotypes (Ansari et al., 2003; Anderson, Joller and Kuchroo, 2016), their role in SSc 
has only just begun to be elucidated (Ayano et al., 2015; Chiba et al., 2017; Fukasawa et 
al., 2017). Understanding how these checkpoints of the immune system play a role in 
disease pathogenesis is an important step towards potential new treatments for a disease 
with few current treatment options. 
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